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DNP Practice Inquiry Project Overview 
“The impending crisis, which has been foreseen for decades, is now upon us.  
The nation needs to act now to prepare the health care workforce to meet the care needs of older 
adults.” Institute of Medicine. 
 
 Given the rising tide of people over the age of 65, taking multiple medications or 
polypharmacy is a becoming more prevalent in older adults. Unfortunately, there are many 
negative consequences associated with polypharmacy. Specifically, this burden has been 
associated with greater health care costs and an increased risk of adverse drug events, drug-
interactions, medication non-adherence, reduced functional capacity and multiple geriatric 
syndromes including cognitive impairment. Cognitive impairment, seen with both delirium and 
dementia, has been associated with polypharmacy. Current medical practice guidelines often 
require multiple medications to treat each chronic disease state for optimal clinical benefit. 
Cognitive impairment can put a patient at risk for either under- or overtreatment due to their 
numerous chronic illnesses requiring treatment. 
 In Primary Care, the burden of polypharmacy can be daunting, especially when patient 
visit times are short and there are other issues to be addressed. There is a lack of an evidence-
based, step-by-step protocol to address polypharmacy in Primary Care that can take the 
healthcare provider and patient through the medication list together, efficiently. If there was such 
an instrument, polypharmacy could be focused on and adverse reactions such as hospitalizations, 
falls, and cognitive impairment could be avoided. The purpose of this DNP project is to 
investigate the impact of polypharmacy on older adults and what is available in the literature to 
address this problem in primary care. Then implement a streamlined Polypharmacy Protocol in 
this type of setting to investigate its positive and negative attributes for future use to apply to the 
problem of polypharmacy. 
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Abstract 
 
 While all types of elder abuse and neglect are serious problems affecting thousands of 
vulnerable elders, financial exploitation has especially serious implications for the victims’ 
economic well-being and quality of life.  Older adults living independently may suffer from mild 
cognitive impairment or take multiple drugs, known as polypharmacy, causing drug interactions 
that could lead to potential mental confusion. These cognitive deficits may frame an older adult 
to be taken advantage of unsuspectingly. Financial exploitation may deprive the victims of their 
life savings and assets and thus their economic foundation for independence. Current legislation 
focuses on identifying scams designed to strip seniors of their assets by helping seniors, their 
families, and caregivers identify and avoid fraud schemes. There is also regulations to improve 
the complaint system for seniors involved in fraud schemes and enhancing the monitoring of the 
types of schemes and number of seniors targeted. The Seniors Fraud Protection Act of 2013 list 
of interventions includes: case management for frail, cognitively impaired elders; preventive 
educational programs; and ongoing collaboration among adult protective services, financial 
institutions, and law enforcement agencies. The purpose of this paper is to appraise current 
legislation in regards to financial and material exploitation of the elderly and the role 
polypharmacy plays with impairing cognition as a possible factor in this detrimental crime. 
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Statement of Issue 
 
 Financial or material exploitation is “the illegal or improper use of an elder's funds, 
property, or assets.” Examples include but are not limited to cashing checks without 
authorization or permission; forging an older person's signature; misusing or stealing an older 
person's money or possessions; coercing or deceiving an older person into signing a document 
(e.g., contracts or a will); and the improper use of conservatorship, guardianship, or power of 
attorney” (Administration on Aging, 1998). In the elderly, an increased number of medications 
can have a negative impact on orientation, memory and judgment leading to more cases of 
financial and material exploitation. Recreational drugs such as alcohol, as well as over-the-
counter (OTC) and prescription medications, may cause a range of cognitive impairments from 
confusion to delirium, and may even mimic dementia (Rogers, Wiese, & Rabheru, 2008). 
Polypharmacy (defined as use of more than five drugs concurrently), is common among older 
adults, and increases the risk of adverse interactions that may interfere with cognition (Rogers et 
al., 2008). Age and disease-associated changes in brain neurochemistry combined with 
polypharmacy to treat multiple chronic diseases, can predispose an older adult to not recognize 
financial or material exploitation (Moore & O’Keeffe, 1999). 
Background 
 
Magnitude of issue 
 
 A Federal Reserve Survey of Consumer Finances for 2010 found that households with 
people 65 and older had approximately one-third of the wealth of the United States 
(Administration on Aging, 2010).  Elder fraud is becoming more prevalent as the overall 
population ages and possibly suffers from cognitive impairment while taking multiple 
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medications to control chronic diseases. According to the Administration on Aging (2010), the 
older population is defined as those 65 or older, and there will be about 72.1 million Americans 
that meet this demographic by 2030, representing 19 %of the population. Nearly one-half (48%) 
of the victims of financial/material exploitation were 80 years of age and older, while another 
28.7% were between 75 and 79 years of age (Administration on Aging, 2010). Next, elderly 
victims between 70 and 74 years of age and those between 65 and 69 accounted for 10.8% and 
9.4%, respectively (Administration on Aging, 2010). Victims between 60 and 64 years old 
accounted for 3.1% of financial/material exploitation. Friends/neighbors (15%), hospitals 
(14.2%), and family members (14%) were the three most frequent reporters of substantiated 
financial/material exploitation (Administration on Aging, 2010). Elder fraud costs U.S. seniors 
$3 billion a year, according to a report from Federal Trade Commission (Mushnick, 2013).    
 Psychological researchers suggests that age-related changes in memory, cognition, and 
emotion can make elderly Americans more vulnerable to fraud and leading to underreporting of 
victimization (Administration on Aging, 1998). Researchers have concluded that approximately 
80 percent of elder abuse cases may go unreported (Curtis, 2006). In most cases, the reporting 
party is not the victim, but rather a family member, friend, caregiver, or advisor. There are a 
variety of reasons that elderly victims do not report abuse, including the following: a) belief that 
they are to blame, b) sense of shame or embarrassment, c) emotional or economic dependence on 
the abuser, d) fear of separation from home or family, e) fear of the criminal justice system, and 
f) lack of knowledge of their rights and alternatives available to them (Curtis, 2006). When 
crimes are not reported, victims may not receive supportive services and perpetrators are free to 
continue victimizing others (Curtis, 2006).  
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 A study, published in the Clinical Gerontologist, entitled “Is psychological vulnerability 
related to the experience of fraud in older adults?” the authors reviewed financial exploitation of 
any kind within the older adult population (Lichtenberg, Stickney, & Paulson, 2013). The study 
included 4400 participants and highlighted prospective predictors of reported financial fraud 
victimization of older adults including those who are psychologically vulnerable (Lichtenberg et 
al., 2013). Those elders, who had the highest level of depression, more medications on their 
regimen, and perceived low social-status, were more vulnerable to experience financial fraud 
(Lichtenberg et al., 2013).  
 Financial exploitation is pervasive among all races, social economic status, and gender. 
Funds lost from exploitation that could be used to pay for basic needs such as housing, food, and 
medical care, effects every demographic. Financial/material exploitation was the third most 
frequent type of elder abuse behind neglect and emotional/psychological abuse involving 30.2% 
of the victims (Administration on Aging, 2010). Female elders were victims of financial/material 
exploitation somewhat more than their proportion of the elder population (63% vs. 57.6%), while 
male elders were victims of exploitation 37% of the time. The proportion of white victims of 
financial/material exploitation was 83% (Administration on Aging, 1998). Black elders 
comprised 15.4% of abuse victims of this type of elder maltreatment (Administration on Aging, 
2010).  
Historical health policy overview 
 
 It is only in recent decades that elder mistreatment as a social policy issue has moved to 
the forefront of health care and social services in the United States. The passage of Medicare, 
Medicaid, and the Older Americans Act legislation in the 1960s was a shift toward increased 
awareness to welfare issues impacting the elderly (Falk, Baigis, & Kopac, 2012). In 1974, Title 
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XX of the Social Security Act authorized the support of protective services to adults 18 years of 
age and older at all income levels who were suffering abuse, neglect, or exploitation. This 
legislation stimulated the creation of Adult Protective Services at the state level.  
 In 1987, the Administration on Aging, as part of the Department of Health and Human 
Services, established the Prevention of Elder Abuse, Neglect, and Exploitation program. 
Through the program, the Administration on Aging provides federal leadership in strengthening 
elder justice strategic planning and direction for programs, activities, and research related to 
elder abuse awareness and prevention. This program trains law enforcement officers, health care 
providers, and other professionals on how to recognize and respond to elder abuse; supports 
outreach and education campaigns to increase public awareness of elder abuse and how to 
prevent it; and supports the efforts of state and local elder abuse prevention coalitions and 
multidisciplinary teams. The situation improved in 2003 when Senator John Breaux introduced 
the Elder Justice Act in the U.S. Senate to highlight the human rights issue of freedom from 
abuse and exploitation (Falk, et al., 2012). 
 In March of 2010 the Elder Justice Act was passed as a law to authorize the expenditure 
of the federal funds to implement the law and provide benefits to elders nationwide. It is 
regarded as the most comprehensive bill ever passed to combat elder abuse, neglect, and 
exploitation (Falk, et al., 2012). The Elder Justice Act authorizes $770 million in spending in the 
years 2010-2014. Of this total, approximately $500 million has been earmarked for Adult 
Protective Services (APS) (Falk, et al., 2012). In May 2013, new legislation that assist the Elder 
Justice Act in combating elder financial fraud, is a bill entitled The Senior Fraud Prevention Act. 
It was introduced in the United States House of Representatives and Senate to focus attention on 
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monitoring the market for mail, television, Internet, and telemarketing fraud including recorded 
message telephone calls (robocalls) targeting seniors.  
 The Senior Fraud Prevention Act of 2013 directs the Federal Trade Commission (FTC) to 
establish an office within the Bureau of Consumer Protection to advise the FTC on the 
prevention of fraud targeting seniors and to assist the FTC in monitoring the market for mail, 
television, Internet, and telemarketing fraud including recorded message telephone calls 
(robocalls) targeting seniors (House Bill 1953 Summary & Status, 2013). This will help protect 
seniors from fraud schemes by strengthening the complaint system to ensure complaints of fraud 
are handled quickly by the appropriate law enforcement agencies. The bill would also require the 
FTC, to coordinate with other agencies to monitor the market for fraud schemes targeting 
seniors. In addition, the bill would require the FTC to distribute information materials to seniors, 
their families, and their caregivers that explains the process for contacting law enforcement 
authorities in the event that a senior is targeted in a fraud scheme.  
Conceptual Framework 
 
 In John Kingdon’s Agendas, Alternatives, and Public Policies (2011) he states that there 
are three stages in the policymaking process: initiation, formulation and implementation. He 
devised a model that comprises three “streams” that flow individually but are important in the 
policymaking process. When two or three streams meet, a policy or bill will move forward. The 
three streams are: The recognition of something as a problem (problem stream); the 
identification of possible solutions (proposal stream); the necessary opportunities at the time of 
the item being added to public policy (political stream).  
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 The problem stream involves persuading policy makers to pay attention to one problem 
over other problems. This is also known as agenda setting. Policy proposals will rise to the top of 
the agenda when the associated problem is recognized as important. This depends on how it is 
framed or brought to policy maker’s attention. The proposal stream is the process by which 
policy proposals are generated, debated, revised, and put forth for consideration. For the policy 
proposal to be successful it must be perceived as feasible, compatible with policymaker’s values, 
reasonable in cost, and appealing to the public (Kingdon, 2011). The political stream refers to 
the factors that influence agendas. This includes “swings of national mood, vagaries of public 
opinion, election results, changes of administration, shirts in partisan or ideological distributions 
in Congress, and interest group pressure campaigns” (p.87). 
 
 The Senior Fraud Prevention Act of 2013 aligns with Kingdon’s Three Streams 
framework. There was recognition of the rising incidences of elder exploitation by the public but 
also by policy makers, thrusting this issue to the top of the agenda or problem stream. A 
bipartisan proposal was created, revised, and introduced by sponsors in both the Senate and 
House of Representatives. This indicates that the Senior Fraud Prevention Act flows into the 
proposal stream since it is feasible, compatible with the all of the policymaker’s values, 
reasonable in cost, and appealing to the public (Kingdon, 2011). The factors that influence 
agendas of the political stream for this policy include interest groups campaigns to raise 
awareness of elder exploitation and fraud, public opinion on the topic, and the ideology of the 
congress men and women who put forth the Senior Fraud Prevention Act. Supporting The Senior 
Fraud Prevention Act of 2013 with Kingdon’s Three Streams framework demonstrates that there 
is a high probability of this policy moving forward through the political process and becoming 
law. 
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Discussion 
 The Senior Fraud Prevention Act of 2013 is an important policy and strategy to address 
the detrimental effects exploitation has on the elderly. Exploitation isolates the victim and 
promotes a sense of helplessness, hopelessness, and/or powerlessness. Early intervention and 
reporting can prevent devastating emotional and financial losses for older persons who have 
worked their entire lives to become financially independent. This policy will give seniors and 
their families the tools they need to avoid scams before they happen, and will also help make 
sure that when a complaint is filed, it gets into the right hands so it can be addressed swiftly and 
effectively. According to US Senators Amy Klobuchar and Susan Collins who introduced this 
policy, the bill would help protect seniors from fraud by establishing an advisory office within 
the Bureau of Consumer Protection (Klobuchar, 2013).  The Bureau of Consumer Protection 
office would be responsible for increasing oversight, consumer education, and establishing a 
complaint tracking system focused on scams that target our seniors (Klobuchar, 2013). 
 In the article entitled Financial exploitation of older persons: Policy issues and 
recommendations for addressing them (2004), the authors address several policy issues and 
make recommendations for an effective public policy approach to combatting financial 
exploitation of elders. These recommendations are considered to be part of the plan to improve 
social service, legal and criminal justice systems’ response to victims of financial exploitation 
(Rabiner, Brown, & O’Keeffe, 2004). The policy options include: understand risk factors for 
victimization; understand perpetrators of financial exploitation; accurate reporting of incidence 
and prevalence data; understand the full impact of financial exploitation; determine effectiveness 
of money management programs; key elements of successful prosecution of financial crimes; 
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reduce the misuse of powers of attorney; effectiveness of financial exploitation prevention 
messages; improve the process for appointing and monitoring guardians; establish restitution 
programs; and multidisciplinary training on financial exploitation (Rabiner, et al., 2004). 
 The Senior Fraud Prevention Act 2013 is focusing on accurate reporting of the incidence 
of fraud in an effort to disseminate information to seniors, their families, and caregivers, on the 
most common fraud schemes. This information will go directly to the FTC where complaints 
will be directed to the Federal Bureau of Investigation, state attorney general’s office, and law 
enforcement agencies for further investigation. This will allow for evaluation of effectiveness of 
financial exploitation prevention messages; help better understand risk factors for victimization; 
allow for accurate reporting of incidence and prevalence data; improve the process for 
appointing and monitoring guardians; and understand the full impact of financial exploitation. 
 Taking into consideration the recommendations outlined by Rabiner, Brown and 
O’Keeffe (2004), the following need to be implemented for legislation to be effective: better 
identification of perpetrators of financial exploitation; reduce the misuse of powers of attorney; 
improve the process for appointing and monitoring guardians; establish restitution programs; 
establish key elements of successful prosecution of financial crimes and multidisciplinary 
training on financial exploitation. Several national groups such as the National Council on Aging 
and AARP (American Association of Retired Persons) have published news releases and 
information on how to combat elder financial fraud. These types of news releases disseminate 
information to seniors, their caregivers, and families, on how to protect their loved ones from 
financial exploitation.  
 Possible implementation issues with the Senior Fraud Prevention Act of 2013 include its 
vast outreach issues. Since the older adult population is continuously increasing in the United 
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States, discerning information about the latest financial fraud scams and victimization reports is 
going to take not only federal leadership but state and local agency leadership as well. Once this 
public policy is implemented, it must be reconciled with already existing policies regarding the 
issue of elder exploitation as highlighted in the historical context of this paper. Once this policy 
is approved into law, if it is dependent on a certain level of funding or participation, this will 
ultimately be the deciding factor in how far this policy will go towards battling the issue of 
financial exploitation. Also, for the Senior Fraud Prevention Act of 2013 to succeed it must be 
supported publicly by local agencies that are a part of this fight to help seniors avoid 
exploitation.  
Conclusion 
 Due to age and disease-related changes in the brain and how the brain manages 
medications, can cause drug interactions leading to potential mental confusion. Polypharmacy is 
common among older adults and increases the risk of adverse interactions that may interfere with 
cognition. These cognitive deficits may cause an older adult to be taken advantage of 
unsuspectingly. Financial exploitation is one type of elder abuse that affects thousands of 
vulnerable elders that can deprive the victims of their life savings and assets and thus their 
economic foundation for independence. The Seniors Fraud Protection Act of 2013 is current 
legislation that focuses on fighting scams designed to strip seniors of their assets and prevent 
devastating emotional and financial losses for older persons who have worked their entire lives 
to become financially independent. This policy will give seniors and their families the tools they 
need to avoid scams and allow for proper follow-up when a complaint is filed, so it can be 
addressed effectively to prevent further exploitation to older adults. 
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Abstract 
 
Purpose: The purpose of this literature review is to critically evaluate published protocols on 
polypharmacy in adults ages 65 and older that are currently used in primary care settings that 
potentially lead to fewer adverse drug events.   
Methods: A review of OVID, CINAHL, EBSCO, Cochrane Library, Medline, and PubMed 
databases was completed using the following key words: protocol, guideline, geriatrics, elderly, older 
adult, polypharmacy, and primary care. Inclusion criteria were: articles in medical, nursing, and 
pharmacology journals with an intervention, protocol, or guideline addressing polypharmacy that 
lead to fewer adverse drug events. Qualitative and quantitative studies were included. Exclusion 
criteria were: publications prior to the year 1992. 
Results: A gap exists in the literature. No standardized protocol for addressing polypharmacy in the 
primary care setting was found. Mnemonics, algorithms, clinical practice guidelines, and clinical 
strategies for addressing polypharmacy in a variety of healthcare settings were interspersed 
throughout the literature. Several screening instruments for use in primary care to assess potentially 
inappropriate prescription of medications in the elderly, such as the Beers Criteria and the STOPP 
screening tool, were identified as well. However, these instruments were not included in a 
standardized protocol to manage polypharmacy in primary care. 
Conclusion: Polypharmacy in older adults is a critical problem that may result in adverse drug 
events such as falls, hospitalizations, and increased expenditures for both the patient and the 
healthcare system. No standardized protocol to address polypharmacy was located in the literature. 
Given the growing population of elderly in this country and the high number of medications they 
consume, it is critical to focus on the utilization of a protocol to address polypharmacy in primary 
care and evaluate its effects on patient outcomes. 
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Introduction 
 There is a lack of consensus on the definition of polypharmacy among healthcare 
professionals. The two most common definitions are the use of potentially inappropriate drugs 
and the concurrent use of five or more medications including prescription and over-the-counter 
drugs (Bushardt, Massey, Simpson, Ariail, & Simpson, 2008). Polypharmacy is distinct from 
polymedicine, which is the use of many medications to treat multiple health problems (Michoki, 
2001). The elderly, defined as those aged 65 years and older, have on average six co-morbid 
chronic conditions that require multidrug therapy to cure, slow progression, or reduce the 
symptoms of disease (Bushardt et al., 2008). Evidence based guidelines recommend several 
drugs in the treatment or prevention of a single medical condition such as in the case of diabetes 
mellitus or heart failure (Viktil, Blix, & Reikvam, 2008). The elderly tend to consume more 
over-the-counter (OTC) products than any other demographic group and account for 30% of 
OTC drug use in the U.S. (Francis, Barnett, & Denham, 2005; National Council on Patient 
Information and Education, 2010). Consequently, elderly patients likely take several 
medications, both prescription and OTC, concurrently. There is a multiplicative relationship 
between the number of medications and the number of drug-related problems that occur; with 
each additional medication, the number of adverse reactions rises exponentially (Zurakowski, 
2009).  
 The U.S. Census Bureau projects that by the year 2020 there will be 55 million people 
over the age of 65; this group will represent 20% of the U.S population and consume 50% of 
healthcare costs (Vincent & Velkoff, 2010). Prescriptions for the elderly, account for 25% to 
40% of all prescriptions written in the United States (Ferrario, 2008). Studies have found that a 
larger number of medications used by a patient leads to an increased risk of adverse drug 
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reactions and events, poorer patient compliance, and a larger economic burden (Bregnhoj, 
Thirstrup, Kristensen, Bjerrum, & Sonne, 2009). Other consequences of polypharmacy include: 
drug-drug interactions leading to hospitalization; change in functional status; cognitive 
impairment; urinary incontinence; and change in nutrition status (Maher, Hanlon, & Hajjar, 
2014). Adverse drug reactions and other medication related problems such as falls and 
hospitalizations are associated with significant mortality; over 100,000 deaths occur annually in 
the U.S. due to medications at a cost of $85 billion each year (Bilyeu, Gumm, Fitzgerald, Fox, & 
Selig, 2011). The relatively high rates of medication use by elderly in combination with the 
physiologic changes associated with aging such as decreased renal output, hepatic function, 
serum albumin levels, and total body water and lean body mass increase the prevalence of 
medication associated mortality (Bushardt et al., 2008).  
Purpose  
 The use of medications is essential for treating chronic health conditions and maintaining 
quality of life. The use of potentially inappropriate medications is a known risk factor for adverse 
drug reactions in the elderly along with polypharmacy and inconsistent adherence to the drug 
regimen (Bilyeu et al., 2011). Inappropriate prescribing is an umbrella term for uncontrolled 
polypharmacy, under-prescribing, the prescription of medications that have more potential risk 
than benefit, and poor prescribing practices by healthcare providers that lead to adverse drug 
events (Penge & Crome, 2013). When a medication is used incorrectly or prescribed 
inappropriately, it can cause physical or psychological harm to a patient (Lam & Cheung, 2012). 
This can lead to increased healthcare utilization and expenditure. Appropriate prescribing by a 
healthcare provider is the fundamental first step in the proper use of a medication (Lam & 
Cheung, 2012). Evidence-based prescribing and following guideline directed therapy allows the 
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prescriber to be more confident and avoid adverse outcomes. However, if the medication has the 
potential for more risk than benefit to a patient or a safer, more effective alternative is available, 
this medication is considered inappropriately prescribed (Lam & Cheung, 2012).  
 Improving prescribing practices and decreasing adverse drug events in the elderly would 
have significant health and financial benefits. To produce these results, improved medication 
reconciliation and prescribing by the healthcare provider must be initiated to reduce the number 
of potentially inappropriate medications prescribed for elderly patients. The purpose of this 
literature review is to critically evaluate evidence based protocols on polypharmacy in elderly 
patients in the primary care.  
Methods 
 Using the key words “protocol”, “guideline”, “geriatrics”, “elderly”, “older adult”, 
“polypharmacy”, and “primary care”, the OVID, CINAHL, EBSCO, Cochrane Library, Medline, 
and PubMed databases were searched. Articles published in the 15 year period from 1998 
through 2013 was chosen for review of the most current state of the evidence. One article 
published in 1992 was included because it contained a well-documented and applied screening 
instrument for practice. Inclusion criteria were: articles in medical, nursing, and pharmacology 
journals with a protocol or clinical practice guideline or other clinical strategy for polypharmacy 
that led to fewer adverse drug events as the outcome variable. A clinical practice guideline is 
designed to support decision-making processes in patient care with content based on a systematic 
review of the clinical evidence. A protocol is viewed as more specific than a guideline, as it 
provides a comprehensive set of criteria outlining the management steps for a single clinical 
condition (Field & Lohr, 1992). Qualitative and quantitative studies were included. Sixteen 
articles met the criteria for inclusion in this review.  
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 The articles were reviewed using the categories of: (a) Author (Date); (b) Type of Study; 
(c) Sample; (d) Purpose; (e) Findings; (f) Implications; (g) Evidence Level; and (h) Strength of 
Evidence. They were further grouped into subheadings of: Clinical Strategies, Algorithms, 
Acronyms, Guidelines, and Screening Instruments. The Hierarchy of Evidence Rating System 
used was the Strength of Recommendation Taxonomy (SORT) (Ebell et al., 2004). This system 
rates the evidence from Levels A to C, with Level A being consistent, good-quality patient-
oriented evidence. Level B is inconsistent or limited-quality patient-oriented evidence, and Level 
C is consensus, disease-oriented evidence. The SORT system also is used to assess the quality of 
evidence of the studies where Level I is the highest and Level III is the lowest. 
Results  
The search yielded 16 articles that describe a broad range of approaches to address 
polypharmacy in the elderly including: screening instruments to reduce the prescription of 
inappropriate medications by healthcare professionals, expert clinical opinion strategies or 
recommendations, an algorithm for reducing or discontinuing medications, mnemonics for use 
by clinicians while reconciling a medication list, and clinical practice guidelines. Key findings 
from the articles are summarized in the following sections and in the Appendix. 
Screening Instruments 
Screening instruments in the literature can be applied in clinical practice to allow for 
closer monitoring of drug use, application of interventions to decrease adverse drug events in the 
elderly, and better patient outcomes. Four screening instruments were located in the literature: 
the American Geriatrics Society (2012) Beers Criteria; the Screening Tool of Older Person’s 
Prescriptions (STOPP) (Gallagher, Ryan, Byrne, & O’Mahony, 2008); the Medication 
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Appropriateness Index (MAI) (Hanlon, Samsa, Weinberger, Uttech, Lewis, & Feussner. 1992); 
and the Hyperpharmacotherpay Assessment Tool (HAT) (Bushardt at al., 2008). 
The American Geriatrics Society (2012) updated the 2001 Beers Criteria to: improve the 
selection of prescription drugs by clinicians and patients; evaluate patterns of drug use within 
populations; educate clinicians and patients on proper drug usage; and evaluate health-outcomes, 
quality of care, cost, and utilization data. This Systematic Review (Level I Evidence, SORT A) 
encompasses 53 medications or medication classes divided into three categories: potentially 
inappropriate medications and classes to avoid in older adults; potentially inappropriate 
medications and classes to avoid in older adults with certain diseases and syndromes that the 
drugs listed can exacerbate; and medications to be used with caution in older adults. Limitations 
of the Beer’s Criteria are that it does not address potentially inappropriate medications (PIMs) 
commonly prescribed to older adults including drug-drug interactions, dosing of drugs in renal 
impairment, and therapeutic duplication (Penge & Crome, 2013). It also does not provided a list 
of alternative medications, requiring the provider to have patient specific judgment. According to 
Penge and Crome (2013), little evidence supports the use of the Beer’s Criteria in terms of 
clinical outcomes and lack of significant associations between PIMs and adverse drug reactions. 
 Gallagher et al. (2008) developed the Screening Tool of Older Person’s Prescriptions 
(STOPP) to incorporate potentially inappropriate medication use in the elderly, including drug-
drug interactions and duplicate class prescribing, using a Delphi consensus technique with an 18-
member expert panel (Level I evidence, SORT A). Sixty-five medications were identified and 
agreed upon by the expert panel and then recorded under physiologic systems (cardiovascular, 
central nervous, gastrointestinal, respiratory, musculoskeletal, urogenital, and endocrine). 
Gallagher and O’Mahony (2008) conducted a cross-sectional study with 715 elderly patients 
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with consecutive acute hospital admissions to compare the performance of STOPP to the Beers 
Criteria in detecting potentially inappropriate medicines and adverse drug events. STOPP 
identified PIMs in 35% of patients compared with only 25% using the Beers Criteria. Also, the 
STOPP criteria PIMs, unlike Beers criteria PIMs, are significantly associated with avoidable 
adverse drug events (ADEs) in older people with acute illness that cause or contribute to urgent 
hospitalization (Hamilton, Gallagher, & O’Mahony, 2009). Previous studies had not 
demonstrated a consistent association between PIMs in older patients as defined by the Beers 
criteria and avoidable ADEs.  
 Hanlon et al. (1992) developed the Medication Appropriateness Index (MAI), a 10-
component assessment tool, to assist physicians and pharmacists in assessing the appropriateness 
of a medications in elderly patients (Level I evidence, SORT A). The overall inter-rater 
agreement for the MAI was .88 and for medication inappropriateness was .95; the overall kappa 
was .83. The components include efficacy, drug dosage, interactions, cost, and duplications and 
provide a reliable method to assess drug therapy appropriateness. The MAI is not drug specific 
like the Beers or the STOPP criteria. The MAI requires clinical judgment on the part of the 
provider and incorporates explicit instructions to help standardize the process of medication 
reconciliation with a good inter-rater reliability (Penge & Crome, 2013).  
 The Hyperpharmacotherpay Assessment Tool (HAT) was adapted from Bergman’s 
Medication Management Guideline (2006) for residents in long-term care (Level III evidence, 
SORT C). Bushardt et al. (2008) designed the HAT to meet six goals to avoid polypharmacy: 
monitor number of medications; decrease inappropriate drug use; decrease inappropriate 
pharmacology; optimize dosing regimen; organize sources of medication; and educate the 
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patient. Additional research is needed to refine this instrument since it has not been validated in 
clinical practice.  
Clinical Strategies 
 Clinical strategies and recommendations are available to enhance clinician and patient 
awareness of polypharmacy, to reduce its risks and drug costs. Three clinical strategies were 
identified in this review of the literature. They include a pharmacist directed education 
intervention program (Zarowitz, B.J., Stebelsky, L.A., Muma, B.K., Romain, T.M, & Peterson, 
E.L., 2005), nine key questions to address polypharmacy in the elderly (Bushardt, R. L. & Jones, 
K.W., 2005), and safe prescribing suggestions to avoid the pitfalls of polypharmacy 
(Zurakowski, T., 2009).  
 In a longitudinal, time series cohort study with two interventions separated by one year, 
five categories of high-risk drug combinations were identified to reduce polypharmacy in 
members of a managed care plan (Level II evidence, SORT A). Clinical pharmacists performed 
drug therapy reviews and provided education to physicians and patients about drug safety and 
ways to correct problems with polypharmacy (Zarowitz et al., 2005). This intervention reduced 
drug costs and number of prescriptions in patients at high risk for adverse drug events due to 
polypharmacy. The overall rate of polypharmacy events decreased from 29.01 to 9.43/1,000 
patients (a 67.5% reduction) after the first intervention. After the second intervention, the overall 
rate decreased from 27.99 to 17.07/1,000 (a 39% reduction). The use of pharmacists to provide 
clinical information, decision support, patient self-management, and care delivery redesign 
solved some of the problems resulting from polypharmacy (Zarowtiz et al., 2005).  
 Bushardt and Jones (2005) in an expert opinion article, outlined nine key questions to ask 
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during a primary care visit to address polypharmacy in the elderly and help patients avoid 
medication-related problems (Level III evidence, SORT C).  
Table 1. Nine key questions to address polypharmacy in the elderly 
1) Is each medication necessary? 
2) Is the drug contraindicated in the elderly? 
3) Are there duplicate medications? 
4) Is the patient taking the lowest effective dosage? 
5) Is the medication intended to treat the side effect of another medication? 
6) Can the drug regimen be simplified? 
7) Are there potential drug interactions? 
8) Is the patient adherent? 
9) Is the patient taking an OTC medication, herbal product, or another person’s medication? 
 
 To address the harm of polypharmacy in the elderly, Zurakowski (2009) provided a 
framework based on expert opinion for safe prescribing in the elderly to avoid medication related 
problems (Level III evidence, SORT C). The recommendations included: review the medication 
list at every visit; evaluate the patient’s adherence; consider every new symptom or complaint as 
a possible drug-related problem and investigate it; use the Beers Criteria (2012) as a filter when 
considering a new medication and identify potentially inappropriate medications used in the 
elderly; ensure that each medication on the list has a clear indication; ask about the use of OTC 
products; “start low and go slow” when prescribing; and consult another healthcare professional 
such as pharmacist on a regular basis.  
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Algorithm 
Algorithms are a streamlined method to approach a problem in the clinical setting. They 
have the potential to be an efficient and safe technique to reduce the adverse effects of multiple 
medications in elderly patients. Only one algorithm was found in the literature: the Good 
Palliative-Geriatric Practice algorithm (Garfinkel & Mangin, 2010). 
Garfinkel and Mangin (2010) tested the feasibility of the Good Palliative-Geriatric 
Practice algorithm in a cohort study to improve drug therapy in community-dwelling elderly 
patients (Level II evidence, SORT A). This algorithm takes the healthcare provider through a 
series of yes and no stages to either stop a drug, shift to another drug, continue with the same 
drug, or reduce the dose of the current drug. Of the 70 elderly patients in the study, successful 
discontinuation of medications not immediately essential for life was achieved for 81% with no 
significant adverse events or deaths attributable to discontinuation. Also, 88% of patients 
reported global improvement in health.  
Mnemonics 
 Several publications listed mnemonics as a pattern of letters or associations to assist 
healthcare providers in remembering strategies to reduce polypharmacy in the elderly. Four 
mnemonics were located in the literature: SAIL (Lee, 1998), AMROR (Haque, 2009), TIDE 
(Shah & Hajjar, 2012), and MASTER (Hoskins, 2011). The four mnemonics are listed in Table 2 
but not in the Appendix since they are a technique that aids information retention and not studied 
extensively. 
Table 2. Mnemonics to reduce polypharmacy in the elderly 
SAIL (1998) 
S simple; prescribing drugs that can be taken once a day or adding a combination pill when a 
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second pill must be added keeps a patient’s drug regimen uncomplicated. 
A adverse; the clinician must have knowledge of the adverse effects of all the drugs a patient is 
taking to avoid medication interactions 
I indication; there must be a clear indication for each drug a patient is taking with a desired 
therapeutic goal in mind 
L is for list; the patient’s medication list must be accurate including OTC products, herbs, and 
alternative medications and correspond to their medical diagnoses. 
ARMOR (2009) 
A assess the individual for the total number of medications and for certain groups of medications 
that have potential for adverse outcomes in the older adult such as beta blockers, 
antipsychotics, and antidepressants 
R review for possible drug-drug, drug-disease, and drug-body interactions 
M minimize nonessential medications that lack a clear indication; the risks outweigh the benefits 
that could have a negative outcome on primary functions such as appetite, bladder/bowel, 
activity, and mood 
O optimize by addressing duplication of drugs, adjustment of drugs for renal and hepatic 
function, reducing oral hypoglycemics, and monitoring anticoagulants and seizure medications 
carefully 
R reassessment of the patient’s vital signs, cognitive status, function, and medication compliance 
TIDE (2012) 
T time; allow sufficient time to address and discuss medication issues during each encounter 
I individualize; apply pharmacokinetic and pharmacodynamics principles to regimens by 
adjusting doses for renal and hepatic impairment and starting medications at the lowest 
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effective dose 
D drug interactions; consider potential drug-drug and drug-disease interactions 
E educate; educate the patient and caregiver about non-pharmacological and pharmacologic 
treatments along with side effects and monitoring parameters 
MASTER (2011) 
M minimize drugs used 
A alternatives that should always be considered, especially non-drug therapies 
S start low and go slow 
T titrate therapy, adjusting dose based on individual response 
E educate the patient and family member with clear, written instructions 
R review regularly 
Clinical Practice Guidelines and Quality Indicators 
 Clinical practice guidelines are an evidence-based strategy to address a clinical issue such 
as polypharmacy. The aim of a guideline is to direct decisions and criteria regarding diagnosis, 
management, and treatment in specific areas of healthcare. Two guidelines met inclusion criteria 
for this review of the literature: Assessing Care of Vulnerable Elders (Wenger, Roth, & Shekelle, 
2007) and Improving Medication Management for Older Adult Clients Residing in Long-term 
Care Facilities (Bergman, 2013). 
 Assessing Care of Vulnerable Elders (Wenger et al., 2007) is a set of evidence-based 
quality indicators designed to measure the quality of care of vulnerable adults in the United 
States (Level I evidence, SORT A). There are 26 conditions described to identify areas of care in 
need of improvement. This includes medications to avoid in the elderly along with domains of 
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care including screening and prevention, diagnosis and treatment, and follow-up. The quality 
indicators are not considered the same as practice guidelines. Rather they set a standard that if 
not met can identify poor-quality care and are processes of care that are amenable to direct action 
by providers. Practice guidelines, in contrast, strive to define optimal care in the context of 
complex medical decision-making. According to Penge and Crome (2013), the disadvantage of 
this quality indicators project was the lack of evidence of its validity in practice. 
 Improving Medication Management for Older Adult Clients Residing in Long-term Care 
Facilities (Bergman, 2013) is a guideline to maintain function, decrease polypharmacy, avert 
adverse drug reactions, and avoiding inappropriate prescribing by healthcare providers (Level I 
evidence, SORT A). The guideline identified individuals at risk for problems with medications 
as those who: self-treat, lack coordinated care, were recently discharged from the hospital, have 
impaired cognitive status, and were on complicated medication regimens. The goal is to provide 
long-term care residents with periodic reviews by both a clinician and a pharmacist to review 
medications for congruency with diagnoses, remove duplicate medications, assess renal function, 
and remove high-risk medications from the list when compared to the Beers Criteria (2012). 
Discussion 
 The Beers Criteria, STOPP instrument, and MAI were developed and studied in clinical 
practice to reduce adverse drug events often found with the concurrent use of medications. 
Inappropriate prescribing can be detected using explicit (criterion-based) or implicit (judgment-
based) prescribing indicators (Hamilton, et al, 2009). The Beers Criteria (2012) and STOPP 
(2008) are explicit or readily observable instruments that must be updated regularly to support 
new drugs on the market and evolving clinical practice. One of the most consistent findings is 
that the use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in the elderly is high-risk, 
" " " "" " " "" "" " ""
29"
showing up on both “drugs-to-avoid” lists as well as drug-disease interactions with heart failure, 
chronic renal failure, and peptic ulcer disease. Also, both the Beers and STOPP criteria include 
tricyclic antidepressants as a class of drugs that can exacerbate a number of conditions including 
falls and cognitive impairment. The MAI (1992) is an implicit tool that is predominantly used as 
a research tool and requires clinical expertise to apply some of the criteria, resulting in variable 
inter-rater reliability (Hamilton, et al., 2009). However, each one of these screening instruments 
provides valuable evidence-based information about inappropriate medications in the elderly. 
The standards outlined in these instruments need to be assimilated into a step-by-step 
management protocol for a clinical condition such as polypharmacy.   
 A balance is required between over- and under-prescribing medications to elderly 
patients as outlined in each of the clinical strategies described in this literature review. Essential 
to avoiding polypharmacy and adverse drug events is to continual reappraisal of the patient’s 
medication regimen and their current clinical status, matching the medication regimen to the 
patient’s condition and goals of care, and weighing the potential risks/benefits of each 
medication. However, the clinical strategies lack a standardized approach for the healthcare 
provider to guide the tailoring of medication regimens to avoid polypharmacy.  
 Mnemonics and other memory aids can be helpful to busy healthcare providers in their 
daily work when trying to recall information that requires memorization. The mnemonics 
described above can assist in remembering the most important parameters when assessing a 
patient's drug therapy. The key factors in the use of mnemonics in medication selection 
emphasize that prescribers consider all possible pharmacotherapeutic alternatives and remind 
them to address issues such as contraindications and precautions. Combining each step of the 
mnemonic to include or exclude medications based on individual patient factors allows the 
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healthcare provider to arrive at the most suitable medication for the patient and avoid 
polypharmacy. 
  The movement towards evidence-based healthcare has generated the development of 
clinical practice guidelines and care indicators to address quality, consistency, and costs. 
Guidelines based on standardized practice are capable of supporting improvements in quality and 
consistency in healthcare and reduce inappropriate variation in practice (Field & Lohr, 1992). 
The drawback to clinical practice guidelines to address polypharmacy is that they do not account 
for patients having several medical diagnoses that require multiple medications. The goal of a 
healthcare provider reviewing a patient’s medication list is to try and avoid adverse drug events 
and drug interactions, but also meet the targets set out by the clinical practice guidelines. 
However, the guideline may not take into consideration each patient’s unique set of health 
priorities when addressing polypharmacy. 
Conclusion 
 There is a need for a simple, time-efficient screening protocol that can be used routinely 
to guide prescribing practice and reduce the rate of adverse drug events in elderly patients in 
primary care settings. Protocols are designed in the healthcare system as a standardized way of 
performing a task that is repeatable and reproducible. The goals of protocols are to produce 
similar results, provide a consistent presentation of data and confidence in results, allow for 
efficient auditing procedures, and possibly prevents errors. 
  To address polypharmacy in primary care, such a protocol should be sensitive, specific, 
include commonly encountered adverse drug events, translate into positive clinical outcomes, 
and have good inter-rater reliability (Hamilton et al, 2009). This protocol should encompass the 
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recommendations highlighted in the articles reviewed in this manuscript. The strategies that are 
important to incorporate in the protocol are: (1) inquiring about the use of over-the-counter 
products; (2) whether or not the patient sees specialist(s) and/or has been recently discharged 
from the hospital; (3) if a medication has been recently added to the regimen to treat the side 
effect of another medication (the prescribing cascade); (4) are there any duplications of 
medications on the list; (5) is the patient consuming any high risk medications as identified by 
the American Geriatrics Society; (6) does each drug in the regimen have a clear indication; (7) 
does the patient exhibit any physiologic changes associated with aging that could potentially 
cause an adverse reaction; (8) and is the patient taking the lowest therapeutic dose of each 
medication. The development and use of a standardized protocol to address polypharmacy in the 
elderly population may lead to fewer adverse drug related events such as falls and 
hospitalizations, thus improving quality and reducing healthcare costs. "
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Appendix 
 
Table 3. Articles Reviewed in Order as Presented in the Text 
 
Screening 
Instruments 
        
Author (Date) Type Sample Purpose Findings Implications Evidence 
Level 
SORT 
Strength of 
Evidence 
Grade 
Strengths 
and 
Weaknesses 
American Geriatrics 
Society (2012)  
 
Systematic 
Review 
N/A Update the previous Beers 
Criteria (2001) using a 
comprehensive, systematic 
review and grading of the 
evidence on drug-related 
problems and adverse drug 
events in older adults.  
The 11-member 
interdisciplinary expert 
panel reviewed 2,169 
articles (446 systematic 
reviews or meta-analyses, 
629 Randomized Control 
Trials, 1,094 observational 
53 medications or 
medication classes 
encompass the 
updated 2012 AGS 
Beers Criteria and are 
divided into 3 
categories: a) 
potentially 
inappropriate 
medications and 
classes to avoid in 
older adults; (b) 
potentially 
inappropriate 
To improve the 
selection of 
prescription drugs 
by clinicians and 
patients, it is 
essential to evaluate 
patterns of drug use 
within populations, 
educate clinicians 
and patients on 
proper drug usage, 
and evaluate health-
outcomes, quality of 
care, cost, and 
Level I A, based on 
consistent 
and good-
quality 
patient-
oriented 
evidence 
Strengths: 
Evidence-based 
approach to 
identifying 
potentially 
harmful drugs in 
the elderly, 
streamlined into 
3 tables for quick 
reference, and 
available in a 
pocket guide for 
clinicians to refer 
to while in 
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studies, and 258 citations). medications and 
classes to avoid in 
older adults with 
certain diseases and 
syndromes that the 
drugs listed can 
exacerbate; (c) 
medications to be used 
with caution in older 
adults. 
utilization data.  practice  
(http://www.amer
icangeriatrics.org
/files/documents/
beers/Pri 
ntableBeersPocke
tCard.pdf) 
Weaknesses: 
does not address 
potential 
inappropriate 
medications 
(PIMs) that are 
common in aging 
including drug-
drug interactions, 
dosing of drugs 
in renal 
impairment, and 
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therapeutic 
duplication; does 
not take the 
patients' views, 
wishes or 
adherence to 
treatment into 
consideration; 
time consuming 
to use in Primary 
Care with short 
visit times. 
Gallagher, Ryan, 
Byrne, & O’Mahony, 
(2008) 
Delphi 
consensus 
technique with 
an 18-member 
expert panel in 
geriatric 
medicine, 
N/A  The STOPP list 
incorporates common 
instances of potentially 
inappropriate prescribing in 
older adults including drug-
drug, drug-disease 
interactions, and drugs 
65 medications were 
identified and agreed 
upon by the expert 
panel and then 
recorded under 
physiologic systems 
(cardiovascular, 
Developed to 
address potentially 
inappropriate 
medication use in 
the elderly, 
especially with 
medications in use 
Level I  A, based on 
consistent 
and good-
quality 
patient-
oriented 
evidence 
Strengths: 
Identified 
potential 
inappropriate 
medications 
significantly 
more than the 
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clinical 
pharmacology, 
clinical 
pharmacy, old 
age psychiatry 
and primary 
care 
which adversely affect 
older patients at risk for 
falls and duplicate drug 
class prescriptions. 
A Delphi consensus 
technique was used with an 
18-member expert panel in 
geriatric medicine, clinical 
pharmacology, clinical 
pharmacy, gero-psychiatry, 
and primary care. 
central nervous, 
gastrointestinal, 
respiratory, 
musculoskeletal, 
urogenital, and 
endocrine) 
in Europe, including 
drug-drug 
interactions and 
duplicate class 
prescribing 
Beers Criteria 
and significantly 
identified 
avoidable adverse 
drug reactions in 
older people that 
cause or 
contribute to 
urgent 
hospitalization. 
Weaknesses: 
Failure to capture 
use of 
nonprescription 
medications; does 
not take the 
patients' views, 
wishes or 
adherence to 
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treatment into 
consideration; 
and time-
consuming to use 
in Primary Care 
with short patient 
visits. 
Hanlon, Samsa, 
Weinberger, Uttech, 
Lewis, & Feussner, 
(1992) 
Pilot study 10 
ambu-
latory, 
elderly 
male 
patients  
Test reliability of a new 
tool to assist physicians and 
pharmacists in assessing the 
appropriateness of a 
medication for a given 
patient  
 
Their overall inter-
rater agreement for 
medication 
appropriateness index 
(MAI) was .88, and 
for medication 
inappropriateness was 
.95; the overall kappa 
was .83. 
Provides a reliable 
method to assess drug 
therapy 
Clinicians rate 10 
explicit criteria to 
determine whether a 
given medication is 
appropriate for an 
individual. The 
criteria are: 
indication, 
effectiveness, 
dosage, correct 
directions, practical 
directions, drug-drug 
Level I A, based on 
consistent 
and good-
quality 
patient-
oriented 
evidence 
Strengths: 
Useful for 
detection of drug-
related problems 
in geriatric 
patients admitted 
to the hospital 
from the 
community and 
reliable with a 
low inter-rater 
variability and 
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appropriateness. interactions, drug-
disease interactions, 
duplication, duration 
and expense. Can be 
applicable as a 
quality care outcome 
measure in health 
services research 
and institutional 
quality assurance 
programs 
positive 
correlation 
between high 
score and drug-
related hospital 
admission. 
Weaknesses: 
Does not take 
under-prescribing 
into account and 
therefore does 
not cover all 
aspects of 
inappropriate 
prescribing; 
studied in the 
older adult in-
patient 
population, not in 
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primary care 
setting; and does 
not take the 
patients' views, 
wishes or 
adherence to 
treatment into 
consideration. 
Bushardt, Massey, 
Simpson, Ariail, & 
Simpson, (2008) 
None N/A The Hyperpharmacotherpay 
Assessment Tool (HAT) 
was adapted from 
Bergman’s Medication 
Management Guideline 
(2006) for residents in long-
term care. 
Has not been tested; 
Needs research to be 
conducted to refine 
instrument and 
establish reliability 
and validity. 
 
6 goals for clinicians 
to avoid 
polypharmacy: 
monitor number of 
medications; 
decrease 
inappropriate drug 
use (drug-drug 
interactions, cost, 
diagnosis congruent 
with medication); 
Level III C, consensus, 
disease-
oriented 
evidence, 
usual practice 
or expert 
opinion 
Strengths: Well-
organized 
instrument to be 
used in a primary 
care setting; does 
address patient 
adherence but 
does not take into 
account the 
patient’s wishes 
or preferences. 
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decrease 
inappropriate 
pharmacology 
(duplications, OTC 
and herbal 
products); optimize 
dosing regimen 
(lowest effective 
dose and adherence); 
organize sources of 
medication (mail-
order or multiple 
pharmacies); and 
patient education.  
 
 
 
Weaknesses: Not 
studied in 
primary care 
setting, cannot 
draw conclusion 
about reliability 
and validity of 
the instrument. 
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Clinical  
Strategies 
        
Author (Date) Type Sample Purpose Findings Implications Evidence 
Level 
SORT  
Strength of 
Evidence 
Grade 
Strengths  
and  
Weaknesses 
Zarowitz, Stebelsky, 
Muma, Romain, & 
Peterson, (2005) 
 
Longitudinal, 
time series 
cohort study 
with two 
interventions, 
separated by 
one year based 
on five 
categories of 
high-risk drug 
combinations 
(polypharmacy 
events) 
195,971 
patients 
enrolled in a 
managed 
care plan 
Objective: To enhance 
physician and patient 
awareness of 
polypharmacy; to 
decrease the risks, drug 
costs, and waste 
resulting from 
polypharmacy; and to 
make the business case 
for reducing misuse, 
overuse, and underuse 
of drugs by reducing 
polypharmacy. 
Overall rate of 
polypharmacy 
events decreased 
from 29.01 to 
9.43/1,000 patients 
(a 67.5% reduction) 
after first 
intervention. After 
second intervention, 
overall rate was 
27.99 to 17.07/1,000 
(a 39% reduction). 
(p=0.001) for all 
measures of 
polypharmacy. 
With the use of 
pharmacists 
providing clinical 
information, 
decision support, 
patient self-
management 
support, and care 
delivery redesign, 
some of the 
problems resulting 
from 
polypharmacy 
could be solved. 
 
Level II 
 
A, based on 
consistent and 
good-quality 
patient 
oriented 
evidence 
Strengths: 
Reduced drug 
costs and number 
of prescriptions in 
patients at risk for 
polypharmacy; 
having a clinical 
pharmacist as part 
of the 
interdisciplinary 
team improved 
outcomes by 
providing 
decision support 
to providers and 
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patient 
education/support. 
Weaknesses: 
Generalizability 
of the study’s 
findings to 
primary care 
because clinical 
pharmacists not 
always available 
in primary care 
settings for 
consultation; 
expense to add 
pharmacist as a 
consultant to 
primary care; and 
despite the 
intervention with 
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increased 
awareness of 
polypharmacy, 
the physicians 
stated they would 
not change their 
prescribing habits. 
Bushardt & Jones, 
(2005)  
Expert opinion N/A Provide a systematic 
approach to assess and 
manage polypharmacy 
in the primary care visit 
See text (Table 1) 
for the nine key 
questions 
To reduce 
polypharmacy and 
help patients avoid 
medication-related 
problems. 
Level III C, consensus, 
disease-
oriented 
evidence, 
usual practice 
or expert 
opinion 
Strengths: 
Assessment 
system for the 
primary care visit 
based on various 
definitions of 
polypharmacy; 
streamlined effort 
to quickly assess 
medication lists of 
patients and ask 
important 
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questions 
regarding 
medication use 
and adherence to 
avoid adverse 
drug reactions. 
Weaknesses: Not 
tested or data 
available to 
determine if the 
nine questions 
have improved 
outcomes in the 
primary care 
setting; does not 
list or advise the 
provider to 
follow-up if 
adjustments made 
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to patient’s 
regimen. 
Zurakowski, (2009)  Expert opinion N/A Provide safe prescribing 
tips for older adults for 
healthcare providers to 
weigh the risks and 
benefits of a medication 
Recommendations: 
review the 
medication list at 
every visit; 
evaluate the 
patient’s 
adherence; 
consider every 
new symptom or 
complaint as a 
possible drug-
related problem 
and investigate it; 
use the Beers 
Criteria (2012) as 
a filter when 
To reduce 
polypharmacy and 
help patients avoid 
medication-related 
problems 
Level III C, consensus, 
disease-
oriented 
evidence, 
usual practice 
or expert 
opinion 
Strengths: 
Resource for 
providers that 
highlights safe 
prescribing tips 
for older adults. 
Weaknesses: Not 
tested or data 
available for 
improved 
outcomes in the 
primary care 
setting; only 
refers to the Beers 
Criteria when 
reviewing a 
patient’s 
! ! ! ! ! ! ! ! ! !! ! !!
45!
considering a new 
medication and 
identify potentially 
inappropriate 
medications used 
in the elderly; 
ensure that each 
medication on the 
list has a clear 
indication; ask 
about the use of 
OTC products; 
“start low and go 
slow” when 
prescribing; and 
consult another 
healthcare 
professional such 
medication list, 
does not refer to 
other screening 
instruments such 
as the STOPP 
criteria or MAI. 
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as pharmacist on a 
regular basis.  
 
 
 
 
 
Algorithm         
Author (Date) Type Sample Purpose Findings Implications Evidence 
Level 
SORT 
Strength of 
Evidence 
Grade 
Strengths 
and 
Weaknesses 
Garfinkel & Mangin, 
(2010)  
 
Cohort study N=70 
community 
dwelling 
older adults 
Use of the Good 
Palliative-Geriatric 
Practice algorithm for 
drug discontinuation 
has been effective in 
nursing home setting. 
Will test feasibility in 
community dwelling 
older adults recording 
The algorithm 
recommended 
discontinuation of 
311 medications in 
64 patients (58% of 
drugs). 81% 
successful 
discontinuation was 
achieved with 2% 
It is feasible to 
decrease 
medication burden 
with the Good-
Palliative Geriatric 
Practice 
algorithm. Clearly 
outpatient 
medication use 
Level II A, based on 
consistent and 
good-quality 
patient 
oriented 
evidence 
Strengths: 
Evidence based 
developed 
algorithm that 
flows easily 
through a series of 
yes or no 
questions and 
when to stop or 
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rate of discontinuation, 
morbidity, mortality, 
and changes in health 
status. 
restarted because of 
reoccurrence of 
disease. No 
significant events or 
deaths were 
attributed to 
discontinuation and 
88% reported global 
improvement in 
health. 
 
among older 
adults is a case 
where “less is 
more.” 
continue a 
medication; use of 
algorithm 
improved the 
overall wellbeing 
of the patients 
participating in 
the study. 
Weaknesses: To 
date, only tested 
on patients in a 
long-term care 
setting and in 
community 
dwelling 
palliative care 
patients; 
challenging to 
apply to 
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medication 
reviews with 
older adults who 
have multiple 
comorbidities that 
require multiple 
medications. 
Clinical Practice 
Guidelines or Quality 
Indicators 
        
Author (Date) Type Sample Purpose Findings Implications Evidence 
Level 
SORT 
Strength of 
Evidence 
Grade 
Strengths 
and 
Weaknesses 
Wenger, Roth, & 
Shekelle, (2007)  
Evidence-based 
quality 
indicator 
guideline  
N/A Provide a measurement 
set to evaluate the care 
provided to vulnerable 
older persons at the 
level of the health 
system, health plan or 
medical group. The 
quality indicators are 
linked to scientific 
Twenty-six 
conditions described 
using evidence-
based quality 
indicators to identify 
areas of care in need 
of improvement to 
form the basis of 
interventions to 
In regards to 
polypharmacy, the 
panel of experts 
said to avoid: 
drugs with strong 
anti-cholinergic 
properties; skeletal 
muscle relaxants; 
and high dose 
Level I A, based on 
consistent and 
good-quality 
patient 
oriented 
evidence 
Strengths: 
Developed using 
high-quality 
evidence to form 
processes for 
community-
dwelling elders at 
risk for functional 
decline rather 
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evidence so that 
healthcare providers 
can enhance their 
practice. 
improve care.  benzodiazepines. 
Along with 
recommending 
periodic drug 
regimen review 
and noting clear 
indications for 
each drug on the 
list. 
than outcomes; 
the indicators 
cover the 
common geriatric 
syndromes; and 
the quality 
indicators take 
into account the 
patient’s 
preferences. 
Weaknesses: 
Feasibility in 
primary care 
practice due to the 
indicators being 
designed to 
measure care at 
the level of the 
health system or 
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health plan, not an 
individual 
provider. 
Bergman-Evans, (2013)  Evidence-based 
clinical 
guideline 
N/A To improve medication 
management practices 
by providers for older 
adults in the long-term 
care setting. 
Individuals at risk 
for problems with 
medications were 
those who: self-treat, 
lack coordinated 
care, were recently 
discharged from the 
hospital, have 
impaired cognitive 
status, and were on 
complicated 
medication 
regimens. 
Guideline 
implemented 
through use of 
Medication 
Management 
Outcomes 
Monitor with 4 
outcomes: a) 
maintain function 
b) decrease 
polypharmacy c) 
avoid drug 
adverse events d) 
reduce 
inappropriate 
prescribing 
Level I A, based on 
consistent and 
good-quality 
patient 
oriented 
evidence 
Strengths: 
Evidence-based 
medication 
management for 
complex patients 
with multiple 
medical 
conditions and 
medications; 
highlights 
periodically 
checking 
Creatinine 
Clearance and 
monitoring high 
risk drugs in older 
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adults. 
Weaknesses: Only 
applies to long-
term care 
population, not 
tested in primary 
care setting; 
polypharmacy 
defined as nine or 
more medications, 
a different 
definition than 
found in the 
literature. 
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Abstract 
Purpose: To develop and pilot an evidence-based protocol to address the problem of polypharmacy 
in older adult patients seen in a primary care setting. This protocol will optimize safe and effective 
medication prescribing and use, leading to improved patient care for the older adult patient and less 
adverse events from polypharmacy. 
Methods: A cross-sectional pilot study was conducted to assess nurse practitioner implementation of 
the Polypharmacy Protocol to reduce polypharmacy and inappropriate prescribing in 20 patients, 
ages 60 years and older, seen in a primary care setting. A process evaluation survey, a satisfaction 
survey, and a fidelity assessment instrument were used to evaluate protocol implementation. Data 
from the evaluation and satisfaction surveys were analyzed using descriptive statistics. For the 
process evaluation and satisfaction surveys, summary scores were calculated. 
Intervention: The Polypharmacy Protocol is an 8-step algorithm that systematically takes the 
healthcare provider and patient through pertinent questions while reviewing a patient’s mediation list 
to avoid polypharmacy and its adverse events. 
Results: The mean score for the process evaluation was 3.08 (SD = .73) indicating that the protocol 
was “Just right” in terms of usefulness. The mean score for satisfaction was 4 (SD = 0) indicating 
that all Nurse Practitioners were very satisfied with the protocol. Qualitative feedback from the Nurse 
Practitioners also supported the benefits of using the protocol.  
Conclusion: The Polypharmacy Protocol piloted in this study was demonstrated to be an efficient 
screening instrument that was feasible to use in primary care. In addition, the Nurse Practitioners 
were highly satisfied with it when they used it. The protocol can be used routinely to guide 
prescribing practice and reduce polypharmacy in older adult patients in primary care settings to 
improve quality of life and decrease unfavorable medication events such as falls and hospitalizations. 
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Introduction 
Background and Significance 
 Older adult patients taking multiple medications is known as polypharmacy. The use of 
screening instruments designed to reconcile a patient’s medication list for polypharmacy could 
reduce adverse drug reactions and duplication of medications. Ultimately, this could lead to an 
improvement in the older adult’s quality of life and decrease unfavorable drug events such as 
falls and hospitalizations. The goal of this project was to develop an evidence-based protocol to 
address the problem of polypharmacy in older adult patients seen in primary care. This protocol 
will optimize safe and effective medication prescribing and use, leading to improved patient care 
for the older adult and fewer adverse events from polypharmacy. 
 Older adult patients often take multiple medications for many health conditions which 
results in polypharmacy. There is a lack of consensus on the definition of polypharmacy.  The 
most common definitions are “the use of potentially inappropriate drugs” and “the concurrent 
use of five or more medications” including prescription and over the counter drugs (Bushardt, 
Massey, Simpson, Ariail, & Simpson, 2008). The average older adult, defined as those aged 65 
and older, has six chronic conditions that require multidrug therapy to cure, slow progression, or 
reduce the symptoms of disease (Bushardt et al., 2008). Evidence based guidelines recommend 
several drugs in the treatment or prevention of a single medical condition such as in the case of 
diabetes mellitus or heart failure (Viktil, Blix, & Reikvam, 2008). Also, older adults tend to 
consume more over the counter products than any other demographic group, accounting for 30% 
of over the counter use in the U.S. (Francis, Barnett, & Denham, 2005; National Council on 
Patient Information and Education, 2010). Consequently, this leads to the older adult patient 
concurrently taking several medications, both prescription and over the counter. The relationship 
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between the number of medications and the number of drug-related problems is linear, meaning 
with each additional medication, the number of adverse reactions rises exponentially 
(Zurakowski, 2009).  
 The U.S. Census Bureau projects that by the year 2020 there will be 55 million people 
over age 65 which will represent 20% of the U.S population and who will account for 50% of 
healthcare costs (Vincent & Velkoff, 2010). Prescriptions for the older adults, those age 65 years 
and older, account for 25% to 40% of all prescriptions written in the United States (Ferrario, 
2008). The increased number of medications used by a patient leads to an increased risk of 
adverse drug reactions and events, poorer patient compliance, and a larger economic burden 
(Bregnhoj, Thirstrup, Kristensen, Bjerrum, & Sonne, 2009). Adverse drug reactions and other 
medication related problems such as falls and hospitalizations are associated with significant 
mortality. Medications are associated with more than 100,000 deaths occur annually in the 
United States at a cost of $85 billion each year (Bilyeu, Gumm, Fitzgerald, Fox, & Selig, 2011). 
The relatively high rates of medication use by older adults--in combination with the physiologic 
changes associated with aging such as decreased renal elimination, hepatic function, serum 
albumin levels, total body water, and lean body mass--increase the prevalence of medication 
associated mortality (Bushardt et al., 2008).  
 Patients over the age of 65 years see an average of seven healthcare providers 
(Antimisiaris & Cheek, 2014). For older adults living with five or more chronic conditions this 
number rises to 14 different healthcare providers, averaging over 40 office visits in one year 
(Berenson, 2010). The utilization of specialist healthcare providers and the lack of 
communication between multiple clinicians contributes to polypharmacy in the older adult 
population (Riker & Setter, 2012). With an older adult patient visiting multiple healthcare 
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providers and receiving several prescriptions, the patient is at risk for drug-drug and drug-disease 
interactions along with side effects from each medication. Often times, the older adult patient can 
be subjected to a phenomenon known as the “prescribing cascade” where a medication is added 
to treat the side effect of another medication (Riker & Setter, 2012). This can happen when it is 
not recognized that the initial medication is causing a side effect and the side effect is viewed as 
a new symptom or disease and is therefore treated. Bootman, Harrsion, and Cox (1997) reported 
that for every $1 spent on medications, $1.33 was spent on treating drug-related problems, 
highlighting the significant problems and expenses polypharmacy can cause an older adult. 
 The use of medications has become essential for treating health conditions and 
maintaining quality of life. When a medication is used incorrectly or prescribed inappropriately, 
it can cause physical or psychological harm to a patient (Lam & Cheung, 2012). Inappropriate 
prescribing is a blanket term for unregulated polypharmacy, under-prescribing, the prescription 
of medications that have more potential risk then benefit, and poor prescribing practices by 
healthcare providers that lead to adverse drug events (Penge & Crome, 2013). Inappropriate 
prescribing can lead to increased healthcare utilization and expenditures. Appropriate prescribing 
by a healthcare provider is the fundamental first step in the proper use of a medication (Lam & 
Cheung, 2012).  
 Assessing and managing polypharmacy along with insuring appropriate prescribing in the 
older adult patient can be overwhelming without a systematic approach. With the use of a 
polypharmacy protocol, the healthcare provider will be able to evaluate a patient’s medication 
list and make appropriate changes to decrease polypharmacy and its adverse events thus 
improving quality of care and enhancing safe prescribing practices. The purpose of this pilot 
study was to test an evidence-based research protocol to address polypharmacy in the primary 
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care setting. This included assessing its feasibility to gauge whether or not it is realistic for use in 
the primary care setting. 
Objectives 
The objectives of this study were to: 
1. Conduct a medication review with the Polypharmacy Protocol to modify the patients’ 
regimen, where indicated, to reduce polypharmacy. 
2. Assess nurse practitioners’ prescribing habits to identify inappropriate prescription of 
medications to older adults that may lead to adverse events. 
3. Evaluate the implementation of the Polypharmacy Protocol with a process evaluation survey, 
a satisfaction survey, and a fidelity assessment instrument (i.e., the extent to which delivery 
of the intervention adhered to the protocol). 
Review of Literature 
 Using the key words “protocol,” “guideline,” “geriatrics,” “elderly,” “older adult,” 
“polypharmacy,” and “primary care,” the OVID, CINAHL, EBSCO, Cochrane Library, 
MEDLINE, and PubMed databases were searched. Inclusion criteria were: articles in medical, 
nursing, and pharmacology journals with a protocol or clinical practice guideline or other clinical 
strategy for polypharmacy that led to fewer adverse drug events as the outcome variable. A 
clinical practice guideline is designed to support decision-making processes in patient care with 
content based on a systematic review of the clinical evidence. A protocol is viewed as more 
specific than a guideline, as it provides a comprehensive set of criteria outlining the management 
steps for a single clinical condition (Field & Lohr, 1992). Qualitative and quantitative studies 
were included. Articles published in the 15-year period from 1998 through 2013 were chosen for 
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review of the most current state of the evidence. One article published in 1992 was included 
because it contained a documented screening instrument for practice.  
Sixteen articles met the criteria for inclusion in this review. The articles described a broad 
range of approaches to address polypharmacy in the older adult including: screening instruments 
to reduce the prescription of inappropriate medications by healthcare professionals, expert 
clinical opinion strategies or recommendations, an algorithm for reducing or discontinuing 
medications, mnemonics for use by clinicians while reconciling a medication list, and clinical 
practice guidelines. The articles were reviewed using the categories of: (a) author (date); (b) type 
of study; (c) sample; (d) purpose; (e) findings; (f) implications; (g) evidence level; and (h) 
strength of evidence. They were further grouped into subheadings of: Clinical Strategies, 
Algorithms, Acronyms, Guidelines, and Screening Instruments. The Hierarchy of Evidence 
Rating System used was the Strength of Recommendation Taxonomy (SORT) (Ebell et al., 
2004). This system rates the evidence from Levels A to C, with Level A being consistent, good-
quality patient-oriented evidence. Level B is inconsistent or limited-quality patient-oriented 
evidence, and Level C is consensus, disease-oriented evidence. The SORT system also is used to 
assess the quality of evidence of the studies where Level I is the highest and Level III is the 
lowest. Key findings from the articles are summarized in the manuscript, A Literature Review: 
Polypharmacy Protocol for Primary Care, published in Geriatric Nursing (Skinner, 2015). 
Methods 
Design 
 A cross-sectional pilot study was conducted between April and July 2015 to assess nurse 
practitioner implementation of the polypharmacy protocol to reduce polypharmacy and 
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inappropriate prescribing in older adults, age 60 years and older, seen in a primary care setting. 
Setting 
 The pilot study was conducted at a primary care clinic in Louisville, KY. The Kentucky 
Racing Health Service Center (KRHSC) is an independent clinic not affiliated with a specific 
medical system. The clinic provides health care services for the uninsured, migrant workers that 
look after and train thoroughbred horses at Churchill Downs. At the KRHSC, there are three 
exam rooms complete with computers for documentation and equipment to complete physical 
exams. Staff and personnel include four Nurse Practitioners and a Spanish interpreter. The four 
Nurse Practitioners have 2-10 years of experience as Primary Care Providers. The Spanish 
interpreters are either from Hispanic backgrounds or are Foreign Language graduates in Spanish. 
All are fluent in both English and Spanish are always on site during clinic hours. The clinic 
offers full primary care services including prescriptions, lab work, diagnostic testing, and 
referrals to specialists when needed.  
Sample 
 There were two study samples, (1) the patients who meet the age and polypharmacy 
criteria and (2) the Nurse Practitioners. The data on the purposive sample of patients were 
collected. Four Nurse Practitioners in the primary care clinic piloted the Polypharmacy Protocol 
on five patients each for a total of 20 patients who used five or more medications per day. Male 
and female adult patients age 60 years and older were included. The lower boundary of 60 years 
of age was set due to the large number of adult patients in the primary care clinic who consume 
greater than five medications daily and could benefit from participating in this pilot study. The 
primary care clinic predominately serves a Hispanic population in Louisville, KY, but African 
American and Caucasian patients were seen as well. Patients at this clinic have a variety of 
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common chronic diseases such as hypertension, dyslipidemia, type 2 diabetes, and chronic 
obstructive pulmonary disease that require treatment with multiple medications. 
 Inclusion criteria for the patients were: The use of five or more medications per day and 
age 60 years or older. Exclusion criteria for the patients were: Any patient who had moderate to 
severe cognitive impairment (dementia). Cognition was evaluated by the Principal Investigator 
with the Mini-Cog screening instrument (see Appendices) prior to using the polypharmacy 
protocol. There are three parts to the Mini-Cog that are totaled. A score of 0-2 indicates a 
positive screen for dementia, while a score of 3-5 is a negative screen for dementia. The Mini-
Cog (Borson, Scanlan, Brush, Vitaliano, & Dokmak, 2000) was developed as a brief screening 
tool to differentiate patients with dementia from those without dementia. It takes approximately 
three minutes to administer. The Clock Drawing Test (CDT) component of the Mini-Cog allows 
clinicians to quickly assess numerous cognitive domains including cognitive function, memory, 
language comprehension, visual-motor skills, and executive function and provides a visible 
record of both normal and impaired performance that can be tracked over time. Depending on the 
prevalence of dementia in the target population, the Mini-Cog has sensitivity ranging from 76%-
99%, and specificity ranging from 89%-93% with a 95% confidence interval. This tool has 
strong predictive value in multiple clinical settings (Borson et al., 2003). A score of 3-5 out of 5 
is a negative screen for dementia (Borson et al., 2006), whereas a score of 0-2 out of 5 indicates 
mild cognitive impairment (McCarten et al., 2012).  
 The Mini-Cog has been shown to identify early dementia in nonnative and non-English 
speakers as well as in native English speakers (Doerfinger, 2007). Borson et al. (2000) conducted 
additional testing to examine the tool's accuracy in a "community sample of culturally, 
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linguistically, and educationally heterogeneous older adults" (N = 249). Researchers tested 129 
subjects who met the clinical criteria for probable dementia based on interviews and 120 subjects 
who had no history of cognitive impairment. There were 124 non-English speakers in the 
sample. The sample was 22% African American, 48% Asian American, 17% Hispanic, 7% white 
non-Hispanic, and 6% Native American and other. The Mini-Cog was compared with the MMSE 
and the Cognitive Abilities Screening Instrument (CASI). The Mini-Cog correctly identified 
96% of subjects--more than either of the other tools. It also had the highest sensitivity at 99% (P 
< 0.001). The researchers noted that the Mini-Cog's diagnostic value was not influenced by 
education or language (Borson et al., 2000). The Mini-Cog has been tested in multiethnic and 
multilingual populations without being formally translated (Borson et al., 2000).! !
 Inclusion criteria for the Nurse Practitioners were: hold a Master of Science in Nursing or 
Doctorate in Nursing Practice and licensed as an Advanced Practice Registered Nurse (APRN) in 
the state of Kentucky. Those who practiced at the clinic less than 8 hours per week were 
excluded. The four Nurse Practitioners were approached about participation in this pilot study. 
All agreed to participate after the purpose of the pilot study was described. 
Measures 
 The Polypharmacy Protocol implementation in the community primary care clinic was 
evaluated. This included formative and summative questions as part of a process evaluation to 
determine if the protocol changed the nurse practitioner’s review of the patient’s medication list 
to reduce polypharmacy and improved their prescribing habits with older adult patients. The 
purpose of this process evaluation was to determine if the Polypharmacy Protocol assisted the 
Nurse Practitioners in identifying polypharmacy and potential adverse events. The Nurse 
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Practitioners also evaluated their satisfaction with the protocol.  The four Nurse Practitioners in 
the primary care clinic were asked to complete the process evaluation instrument and satisfaction 
survey after using the protocol with five patients apiece. 
Specifically, three questions were asked: 
1. Is the Polypharmacy Protocol feasible to use in your primary care practice with older 
adults? Feedback was requested with any negative responses (not nearly enough, not 
quite enough) as to why the protocol is not feasible for the primary care setting. 
2. How do you rate your satisfaction with the Polypharmacy Protocol? Recommendations 
or suggestions for improvement for future use were requested. 
3. How much time did it take to administer the protocol? Time can be a factor in how well 
the protocol was adopted and recommendations were requested on how to make the 
protocol efficient in a timely manner for future use. 
 The process evaluation survey outlined in the Appendices was a new instrument created 
specifically for the Polypharmacy Protocol pilot study. Two PhD prepared nurse researchers with 
expertise in survey development and epidemiology reviewed the survey. To improve the validity 
of the protocol, the Principal Investigator was present for each patient visit to ensure the Nurse 
Practitioners consistently administered the Polypharmacy Protocol. Once the pilot study was 
completed, each of the Nurse Practitioners were asked for feedback to identify ambiguities and 
difficult questions along with recording the time taken to complete the protocol.  
 Once the medication review with the Polypharmacy Protocol was completed for all 20 
patients, the Nurse Practitioners completed the two surveys. The first survey provided ordinal 
level data using a Likert scale for feedback on protocol implementation along with 
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recommendations for improvement for future use. The second survey provided ordinal level data 
on their contentment or satisfaction with the protocol using a Likert scale. The Principal 
Investigator used the fidelity assessment instrument created specifically for this pilot study 
during chart audits after implementation of the Polypharmacy Protocol to assess the extent to 
which delivery by the Nurse Practitioners adhered to the originally developed protocol. The 
fidelity assessment determined if adjustments to a patient’s medication regimen were made by 
the Nurse Practitioner to avoid polypharmacy. Examples of questions included in the fidelity 
instrument were: inquiring about OTC medications, if any new medications had been added by a 
specialist or to treat another symptom of a disease, and to remove or decrease the dose of any 
high-risk medications that have been deemed by the American Geriatrics Society as having the 
most adverse effects.  
 The Appendices contain the instruments used in the pilot study. Table 1 describes the 
Process Evaluation instrument used by the Nurse Practitioners after implementation of the 
Polypharmacy Protocol. Table 2 outlines the survey that assessed the Nurse Practitioners’ 
satisfaction in using the Polypharmacy Protocol. Four questions were adapted from the Client 
Satisfaction Questionnaire CSQ-8 (Attkisson, & Zwick, 1982).  The CSQ-8 is a reliable and 
valid measure of client satisfaction with services or programs; Cronbach’s alpha was .93 
(Attkisson, & Zwick, 1982). Table 3 provides three questions that were part of the fidelity 
assessment instrument. Table 4 includes the measures. 
Intervention Protocol 
 The Polypharmacy Protocol is an 8-step algorithm based on the review of the literature 
findings (see Skinner, 2015). The pertinent conclusions from the review of literature were placed 
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into the algorithm to systematically take the Nurse Practitioner and patient through pertinent 
questions while reviewing the patient’s medication list to avoid polypharmacy and its adverse 
events. The questions included: (1) inquiring about the use of over the counter products; (2) 
whether or not the patient sees a specialist or specialists and/or has been recently discharged 
from the hospital; (3) if a medication has been recently added to the regimen to treat the side 
effect of another medication (the prescribing cascade); (4) are there any duplications of 
medications on the list; (5) is the patient consuming any high risk medications as identified by 
the American Geriatrics Society; (6) does each drug in the regimen have a clear indication; (7) 
does the patient exhibit any physiologic changes associated with aging that could potentially 
cause an adverse reaction; (8) and is the patient taking the lowest therapeutic dose of each 
medication. Each step in the protocol has a clear path based on the patient’s yes or no response, 
including what to do if a medication is discontinued from the list with consulting the specialist, 
monitoring the patient, and reassessing the patient with a follow-up visit. The Polypharmacy 
Protocol for Primary Care can be found in the Appendices. 
Procedure 
 The proposal was approved in March 2015 by the University of Kentucky Medical 
Institutional Review Board. The Principal Investigator obtained written informed consent from 
the four Nurse Practitioners who agreed to use the Polypharmacy Protocol with five patients 
each. No cold calls or direct mailings were conducted to recruit patients. During a scheduled 
office visit, the patients who met screening eligibility were approached by the Principal 
Investigator about the pilot study. In order to avoid coercion, the patients were assured that their 
participation was voluntary and they would not suffer negative consequences involving their 
continued care at the clinic if they chose not to participate. If they chose to participate, they 
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could stop at any time during the study and still keep the benefits and rights they had before 
volunteering. If the patient agreed to participate, the Principal Investigator obtained written 
informed consent in their native language (Spanish or English).  
 After the consent form was signed in their native language, the Principal Investigator 
completed the Mini-Cog instrument to assess for cognitive impairment. Every patient scored 
between 3-5, indicating a negative outcome for cognitive impairment based on recalling three 
objects and drawing the face of a clock appropriately. 
Once consent was obtained and the Mini-Cog was completed, each patient was randomly 
seen by one of the four Nurse Practitioners in the clinic. The patients were requested to bring in 
their home medication list and/or bottles with them to their next scheduled office visit. At that 
visit, the Nurse Practitioner: (1) used the protocol to review the patient’s medication list; (2) 
made appropriate adjustments to reduce the adverse effects of polypharmacy; and (3) assessed 
their own prescribing habits for inappropriate medications. If needed, in order to ensure the 
medication information obtained from the patient was accurate, the nurse practitioner contacted 
the pharmacy where the medications were filled to verify medication the name, dosage, and last 
time the medication was filled by the patient.   
 Privacy of the patients was insured with no use of patient identifiers. Each patient who 
agreed to participate and signed an informed consent form was assigned a study number that 
correlates with the Nurse Practitioner who saw the patient. For example, NP #1’s five patients 
were coded as: NP1-1, NP1-2, NP1-3, NP1-4, and NP1-5. This numbering system continued for 
each of the four Nurse Practitioners and their five patients apiece. After the Principal Investigator 
obtained informed consent from the patients, the consent forms were locked in a file cabinet in a 
secure location at the primary care clinic. 
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 Privacy of the four Nurse Practitioners was insured with no identifiers such as name or 
license number on the two surveys they completed after using the Polypharmacy Protocol with 
their five patients. The Nurse Practitioners’ informed consent forms were locked in a file cabinet 
in a secure location at the primary care clinic. The Nurse Practitioners completed the two surveys 
after completing the Polypharmacy Protocol with their fifth patient. The Principal Investigator 
completed chart audits after implementation of the Polypharmacy Protocol to assess for fidelity 
or the extent to which delivery of the Polypharmacy Protocol by the Nurse Practitioners adhered 
to the originally developed protocol. Data were analyzed using descriptive statistics including 
frequency distributions, measures of central tendency (mean, median and/or mode) for the 4-
point Likert scales. For the process evaluation, summary scores for all of the questions on the 
survey were derived and means were calculated. 
Results  
 Demographic information for the 20 patients who participated in the pilot study included: 
five African Americans, four Caucasians, and 11 Hispanics. The male to female ratio was 14:6 
with the male age range between 60-71 and the female age range between 60-66.  Each patient 
had a minimum of five medications while the highest number found on a regimen was seven 
prescription medications. One patient had a total of 10 medications, four prescribed and six OTC 
products including vitamins and herbal preparations. The most commonly prescribed 
medications found during the pilot study included ACE-inhibitors and Calcium Channel 
Blockers for hypertension, Metformin for treatment of type 2 diabetes, and the family of 
cholesterol drugs known as the statins. The most common OTC medications found during the 
pilot study were NSAIDs (Ibuprofen, Naproxen, and Tylenol), Calcium plus Vitamin D along 
with antacids such as omeprazole. 
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 The Nurse Practitioners used all eight steps of the Polypharmacy Protocol correctly when 
reviewing the patient’s medication list. Table 1 describes the changes made to the patient’s 
medication regimen by the Nurse Practitioners using the protocol. This information was 
collected during the chart audits using the fidelity instrument, post-implementation of the 
protocol.  
Table 1.  Fidelity Instrument for the Polypharmacy Protocol Pilot Study Results 
 
Question Change  
Were OTC medications added to the med list? 
 
 
OTC products such as Multi-vitamins and 
Tylenol were added to 3 out of 20 charts 
Was a note made about specialist or recent 
discharge from hospital with changes to med 
list? 
 
Medication lists were updated based on a 
patient’s recent discharge from the hospital 
for 2 patients 
Was the medication list reviewed and adjusted 
for: Prescribing cascade? 
 
No adjustments were made for problems 
related to the Prescribing Cascade as no 
issues were identified. 
Was the medication list reviewed and adjusted 
for: Duplications? 
 
Duplicate medications were removed from 
2 patients’ medication lists 
Was the medication list reviewed and adjusted 
for: High-risk medications from Table 2? 
 
All patient lists were compared with the 
high-risk medications from Table 2 leading 
to removal of NSAIDs from 2 patients’ lists 
and switching 1 patient’s glyburide to 
another diabetic medication. 
Was the medication list reviewed and adjusted 
for: Matched medication with diagnosis? 
 
All patient medications were matched with 
an appropriate diagnosis. 
Was the medication list reviewed and adjusted 
for: Note any physiologic changes in the 
patient? 
 
Each patient either had recent or was asked 
to have blood work drawn to look for renal, 
liver and protein changes that could affect 
the pharmacokinetics 
Was the medication list reviewed and adjusted 
for: Decrease dose to lowest effective dose? 
 
3 patient medications were decreased to the 
lowest effective dose and monitored closely 
(Ambien, Ultram, Glipizide) 
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 Results for each survey item on the process evaluation are listed in Table 2. For Nurse 
Practitioner satisfaction, summary scores for the four questions adapted from the CSQ-8 were 
calculated and had a mean of 4 (SD = 0.0) indicating there was perfect agreement across all four 
Nurse Practitioners in terms of high satisfaction with the protocol. Results for each item on the 
satisfaction survey are listed in Table 3. Qualitative feedback from the Nurse Practitioners on the 
use of the Polypharmacy Protocol is summarized in Table 4. 
Table 2. Mean and Standard Deviation for Process Evaluation Items (N = 4) 
Item Mean Standard  
Deviation 
Does the protocol include enough background 
information about the problem of 
polypharmacy and inappropriate prescribing? 
 
3 0.0 
Does the protocol allow the APRN freedom to 
individualize the protocol for each patient’s 
medication list review? 
 
3.25 0.5 
Is the protocol feasible/appropriate for an 
APRN in this practice setting? 
 
3 0.0 
Does the protocol provide the minimum 
standard of care for the clinical problem of 
polypharmacy? 
 
3 0.0 
Does the protocol provide the minimum 
standard of care for addressing inappropriate 
prescribing in the older adult population? 
 
3 0.0 
How much time did it take to administer the 
protocol? 
 
3.25 0.96 
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Table 3. Mean and Standard Deviation for Satisfaction Items (N = 4) 
Item Mean Standard  
Deviation 
How would you rate the quality of the 
Polypharmacy Protocol?  
 
4 0.0 
To what extent did the Polypharmacy Protocol 
meet the needs of your practice setting? 
 
4 0.0 
Did the Polypharmacy Protocol help you 
address the problem of polypharmacy and 
inappropriate prescribing in your practice 
setting? 
 
4 0.0 
Overall, how satisfied are you with the 
Polypharmacy Protocol in addressing 
polypharmacy and inappropriate prescribing in 
your practice setting? 
4 0.0 
 
Table 4. Qualitative feedback from the Nurse Practitioners on the use of the 
Polypharmacy Protocol (N = 4) 
 
1. Do you feel that the protocol made you more aware of the problem of polypharmacy 
and its problems? 
• It simplified the Beers criteria 
• Having an algorithm really helped streamline the medication review 
• The protocol re-emphasized potential drug-drug interactions 
 
2. Do you feel that the protocol modified your prescribing habits to avoid inappropriate 
prescribing in older adults? 
• It made me more aware of the over-the-counter interactions 
• Made me more aware of problem drugs 
• Helped to remind me to ask about over-the-counter medications at every visit 
• Helped me to identify drug side effects 
 
3. What are the best features of the protocol? 
• Ease of use 
• Protocol is clear 
• The flow of the algorithm with tables to guide your interview 
• Provided a defined process to logically assess a patient’s medication list 
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4. What are the worst features of the protocol? 
• Trying to explain to the patient your reason for doing the protocol as part of their 
visit 
• None  
 
5. Please list any suggestions you have to improve or change the protocol for use in 
practice. 
• Needs medication reconciliation as part of Step 1 
• Ask about adherence to medications in Step 1 
• Change Step 2 to specialist or other provider who has prescribed medications 
• Add Emergency Room and Urgent Care to Step 2 
• Quantify the term recently in Step 3 as last month/week, since last visit, etc. 
• Define the term prescribing cascade in Step 4 because not all providers are aware 
of this phrase 
• Consider adding to Step 8 titration of medication to most effective dose (as in the 
case of titration of medications to therapeutic dose for medications such as Beta 
Blockers and ACE-inhibitors for Heart Failure patients) 
• Consider adding a Step that asks about the patient’s wishes or preferences 
• Consider adding a Step that takes cost of medication into account 
 
 
Discussion 
 The Polypharmacy Protocol is feasible for use in the primary care practice with older 
adults and received high satisfaction ratings from the Nurse Practitioners. However, time was an 
implementation factor with varying ranges reported by the Nurse Practitioners. Time is an 
important element to consider when initiating a protocol especially in the primary care setting 
where patient visit times can be brief and other issues may take precedence. If the Polypharmacy 
Protocol became part of an Electronic Medical Record (EMR) a provider could simply scroll 
through the algorithm as he or she reviews a patient’s medication list, checking yes or no boxes, 
leading to a quicker review process. Goals for the future with the Polypharmacy Protocol include 
investigating software to incorporate it into an EMR or an application for a smart phone. 
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 The qualitative responses from the pilot study participants yielded the most valuable 
findings. Based on the Nurse Practitioner’s responses to both surveys, the Polypharmacy 
Protocol was reviewed to either discard or revise all unnecessary or ambiguous questions and 
assess whether each question gave an adequate range of responses to establish replies from 
patients that can be interpreted in terms of the information that is necessary to reduce 
polypharmacy. Revisions to the Polypharmacy Protocol based on the feedback will include: 
verifying that what is in the chart is what the patient is currently taking and inquiring about 
medication adherence in Step 1; adding other providers who have prescribed medications along 
with recent Emergency Room or Urgent Care visit to Step 2; quantifying the term “recently” in 
Step 3 to reflect time since the patient’s last visit in the primary care office or clinic; define the 
term “prescribing cascade” in Step 4 as a recently prescribed medication is causing a side effect 
and the side effect is viewed as a new symptom and therefore treated; supplement Step 8, to 
include therapeutic doses for specific disease states; adding a step that prompts the provider to 
ask about the patient’s preferences or wishes regarding their medication regimen; and inserting a 
final step that features inquiring about the cost of medications for the patient. 
Limitations ! Pilot studies are exploratory trials limited in size and scope that give insight into research 
protocols, medications, or medical devices but cannot provide definitive support for specific 
systematic or therapeutic claims (Polit et al., 2001). Individual small-sized studies include 
assessing feasibility, determining potential harm, validating a method for determining an 
outcome measure, and evaluating the organization of the pilot study performance (Loscalzo, 
2009). However, there are associated disadvantages or limitations of pilot studies. The feasibility 
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and acceptability may be misleading if the size is small leading to inadequate power to detect 
harm or other problems (Loscalzo, 2009). Further, a study can only examine feasibility of the 
patient type included in the study making generalizability of the results difficult beyond the 
inclusion and exclusion criteria of the pilot (Loscalzo, 2009). This was the case with the 
Polypharmacy Protocol Pilot Study; it was tested in a single setting with a small number of 
patients and healthcare providers.  
 A pilot study is not a hypothesis testing study and therefore safety and efficacy are not 
evaluated (Leon, Davis, & Kraemer, 2011). However, a pilot study can be clinically meaningful 
if it requires contributions from clinicians who treat the patient population of interest (Leon et 
al., 2011). The Polypharmacy Protocol pilot study was conducted with the goal of seeking the 
input of healthcare providers wanting to improve their practice by avoiding polypharmacy in 
their older adult patients. To ensure that the interpretation of a pilot study is reliable, it must be 
approached rigorously and with the same level of scrutiny as other trials (Loscalzo, 2009). The 
outcomes for the Polypharmacy Protocol pilot study were outlined practically to avoid 
misinterpretation of the results.  
 Additional limitations specific to this pilot study include the highly motivated Nurse 
Practitioners who wanted to see the protocol be successful, the demographics of the patient 
population and the nature of the clinic. The KRHSC fulfills a need in the community for the 
migrant workers in the thoroughbred racing industry who typically only seek care while in 
Louisville, KY. Also, there are differences in the prescribing habits of the providers. Due to not 
billing insurance companies or having access to samples of medications from drug companies, 
the providers primarily prescribe from the generic $4 or $10 medication lists available from local 
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retailers. These types of prescribing habits may not be generalizable to the primary care clinics in 
other areas of the United States.  
 In summary, pilot studies are a necessary first step in exploring new interventions, such 
as a protocol, that are designed to inform the healthcare community of its feasibility. Once 
completed, the intervention can be modified for a larger trial to evaluate its safety and efficacy. 
After revisions are completed on the Polypharmacy Protocol, the next step will be to test it in a 
larger setting such as several community primary care clinics that care for a variety of older adult 
patients.  
Conclusion 
  There is a need for a simple, time-efficient screening protocol that can be used routinely 
to guide prescribing practice and reduce polypharmacy in older adult patients in primary care 
settings. Protocols are designed as a standardized way of performing a task that is repeatable and 
reproducible. The goals of protocols were to produce similar results, provide a consistent 
presentation of data and confidence in results, allow for efficient auditing procedures, and 
possibly prevents errors (Loscalzo, 2009). To address polypharmacy in primary care, such a 
protocol should be sensitive, specific, include commonly encountered adverse drug events, 
translate into positive clinical outcomes, and have good inter-rater reliability (Hamilton et al., 
2009). The Polypharmacy Protocol piloted in this study encompasses these attributes and 
provides a strategy that can be incorporated into practice to reduce adverse drug reactions, 
improve an older adult’s quality of life, and decrease unfavorable events such as falls and 
hospitalizations. 
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Figure 1. Polypharmacy Protocol for Primary Care 
 
Purpose: To address the problem of polypharmacy and inappropriate prescribing in older adult 
patients (age 60 and older) seen in a primary care setting. This protocol will provide a systematic 
approach for the healthcare provider to evaluate a patient’s medication list and make appropriate 
changes to decrease polypharmacy. It will also optimize safe and effective medication prescribing by 
the healthcare provider leading to improved patient care for the older adult and less adverse drug 
events. 
 
Definitions: 
• Polypharmacy—“the use of potentially inappropriate drugs” and “the concurrent use of five 
or more medications” including prescription and over the counter drugs 
 
• Inappropriate Prescribing in Older Adults--unregulated polypharmacy, the prescription of 
medications that have more potential risk then benefit, and poor prescribing practices by 
healthcare providers that lead to adverse drug events. 
 
Appendix 
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Obtain'pa)ent'medica)on'
List/Brown'Bag'
STEP'1'
Take'any'OTC'products?'
(vitamins,'minerals,'herbs)'
YES'
Add'OTC'products'to'medica)on'list'
Note%any%drug-drug%interac0ons?%
%
Common'OTCHprescrip)on'interac)ons'
'1.'St.'John's'Wort'+'SSRI'or'Tricyclic'
An)depressants'
'2.'Tylenol'+'Lortab/Vicodin'
'3.'Antacids'+'Levothyroxine'and'Iron'
supplements'
'4.'Omeprazole'+'Plavix'
'5.'Coumadin'+'Aspirin'or'Gingko'or'Kava'
The'Gerontological'Society'of'America,'2013'
NO'
Go'To'Step'2'
STEP'2'
See'any'specialists?''
OR'
Discharged'from'hospital'
recently?'
YES'
Update'medica)on'list'with'meds'
from'specialist'or'hospital'
NO''
Go'To'STEP'3'
Polypharmacy+Protocol+for+Primary+Care+
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STEP'3'
Was'a'medica)on'added'recently'to'treat'the'side'effect'of'another'medica)on?'
"The'Prescribing'Cascade"'
Ex.'BP'med'for'chronic'NSAID'user''
Ex.'Detrol'for'incon)nence'from'Aricept'
Ex.'An)Hparkinson'med'for'symptoms'from'Reglan'
An)misiari'&'Cheek,'2014'
YES'
Stop'medica)on,'monitor'pa)ent,'and'reassess''
in'1H2'weeks'
(See'Table'1'for'monitoring'guidelines,'
see'Table'3'for'consul)ng'specialists)'
NO'
GO'TO'STEP'4'
STEP'4'
Any'duplica)on'of'medica)ons?'
(same'class)'
Ex.'Lortab/Vicodin'+'Tylenol'ES'
Ex.'Toprol'XL'+'metoprolol'tartrate'
Ex.'Glipizide'+'Glimepiride'
YES'
Discon)nue'duplicates;'monitor'
pa)ent'and'reassess'in'1H2'weeks'
(See'Table'1'for'monitoring'
guidelines)'
NO''
GO'TO'STEP'5''
TABLE+1+
What'to'monitor'on'a'patient'after'
adjusting'dose'or'discontinuing'
medication:'
'
1. Heart'rate'
2. Blood'pressure,'including'
orthostatic'
3. Oxygen'saturation'
4. Weight'
5. Appetite'
6. Sleep'
7. Activity,'including'falls'
8. Bowel/bladder'function'
Haque,'2009'
'
!
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STEP'5'
Note'any'high'risk/dangerous'medica)ons?'
(compare'to'Table'2)'
YES'
If'reasonable,'reduce'dose/stop'high'risk''
medica)on'or'switch'to'safer'drug;'mon)or'pa)ent'
and'reassess'in'1H2'weeks'
(see'Table'1'for'monitoring'guidelines,'
see'Table'3'for'consul)ng'specialists)'
NO''
GO'TO'STEP'6'
TABLE+2+
10'Medications'to'Avoid'or'Use'Caution'in'Older'Adults'
'
1. NSAIDs'
• Especially'with'blood'thinners,'such'as'Coumadin'
2. Lanoxin'(digoxin)'
3. Sulfonylureas'(Glyburide,'chlorpropamide)'
4. Muscle'Relaxants'(Flexeril,'Robaxin,'Soma)'
5. Anxiety/Insomnia'(Valium,'Xanax,'Librium,'Sonata,'Ambien)'
6. Anticholinergic'Drugs'(Amitriptyline,'Bentyl,'oxybutynin)'
7. Demerol'
8. OTC'Drugs'(Benadryl,'chlorpheniramine,'Tylenol'PM)'
9. Antipsychotics'(Haldol,'Risperdal,'Seroquel)'
10. Estrogen'pills/patches''
American'Geriatrics'Society,'2012'
'
***Please'note:'If'discontinuing'a'psychoactive'drug'(antidepressant,'antipsychotic,'neuralgia'
medications,'pain'medications,'and'anticonvulsants)'taper'the'dose'to'avoid'adverse'
withdrawal'effects.'
'
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STEP'6'
Does'each'drug'have'a'clear'
indica)on?'
(Diagnosis'matchs'medica)on)'
NO'
Discon)nue'medica)on(s)'that'
do'not'match'a'diagnosis;'
monitor'pa)ent'and'reassess'in'
1H2'weeks.'
(see'Table'1'for'monitoring'
guidelines,'see'Table'3'for'
consul)ng'specialists)'
YES'
GO'TO'STEP'7'
STEP'7'
Does'pa)ent'exhibit'any'physiologic'changes'
of'aging'that'could'lead'to'poten)al'adverse'
reac)ons?'
1.'Reduced'GFR/Cr'Clearance'
2.'Elevated'liver'enzymes'
3.'Decreased'serum'albumin'
YES'
Reduce'dose'of'medica)on;'
monitor'pa)ent'and''reassess'
pa)ent'in'1H2'weeks'
(see'Table'1'for'monitoring'
guidelines,'see'Table'3'for'
consul)ng'specialists)'
NO'
GO'TO'STEP'8'
STEP'8''
Is'the'pa)ent'taking'the'
lowest'therapeu)c/'
effec)ve'dose?'
YES''
Polypharmacy'
Review'Complete'
NO''
Reduce'dose'of'one'medica)ion'
at'a')me;'monitor'pa)ent'and'
reasses'in'1H'2'weeks'
(see'Table'1'for'monitoring'
guidelines,'see'Table'3'for'
consutling'specialists)'
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Table+3+
+
When'to'consult'specialists'regarding'withdrawal'of'medications:'
'
1. ACE'inhibitors'for'HF'
2. Diuretics'for'HF'
3. Essential'hormones'(longHterm'corticosteroids,'levothyroxine)'
4. Antipsychotics,'mood'stabilizing'drugs'
5. Anticonvulsants'for'seizures'
6. Parkinson’s'medications'
7. Disease'modifying'antiHrheumatic'drugs'
8. Longstanding'benzodiazepines'and'opiates'
CNA,'2013'
'
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Figure 2. The Mini Cog 
Administration:  
1. Instruct the patient to listen carefully to and remember 3 unrelated words and then to 
repeat the words. The same 3 words may be repeated to the patient up to 3 tries to register 
all 3 words.  
2. Instruct the patient to draw the face of a clock, either on a blank sheet of paper or on a 
sheet with the clock circle already drawn on the page. After the patient puts the numbers 
on the clock face, ask him or her to draw the hands of the clock to read a specific time. 
The time 11:10 has demonstrated increased sensitivity.  
3. Ask the patient to repeat the 3 previously stated words.  
Scoring: (Out of total of 5 points) 
• Give 1 point for each recalled word after the CDT distractor. Recall is scored 0-3. 
• The CDT distractor is scored 2 if normal and 0 if abnormal. 
(Note: The CDT is considered normal if all numbers are present in the correct sequence 
and position, and the hands readably display the requested time. Length of hands is not 
considered in the score.)  
Interpretation of Results:  
0-2: Positive screen for dementia  
3-5: Negative screen for dementia  
 
Sources:  
Borson, S., Scanlan, J., Brush, M., Vitallano, P., & Dokmak, A. (2000). The Mini-Cog: A cognitive ‘vital signs’ measure for 
dementia screening in multi-lingual elderly. International Journal of Geriatric Psychiatry, 15(11), 1021-1027.  
Borson, S., Scanlan, J.M., Watanabe, J., Tu, S.P., & Lessig, M. (2006). Improving identification of cognitive impairment in 
primary care. International Journal of Geriatric Psychiatry, 21(4), 349-355.  
Lessig, M., Scanlan, J., Nazemi, H., & Borson, S. (2008). Time that tells: Critical clock-drawing errors for dementia screening. 
International Psychogeriatrics, 20(3), 459-470.  
Copyright S. Borson. All rights reserved. Reprinted with permission.  
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Table 1. Process Evaluation  
 
Question     
Does the protocol include enough 
background information about the 
problem of polypharmacy and 
inappropriate prescribing? 
Not nearly 
enough 
1 
Not quite 
enough 
2 
Just 
right 
3 
More than 
enough 
4 
 
Does the protocol allow the APRN 
freedom to individualize the 
protocol for each patient’s 
medication list review? 
Not nearly 
enough 
1 
Not quite 
enough 
2 
Just  
right 
3 
More than 
enough 
4 
 
Is the protocol feasible/appropriate 
for an APRN in this practice 
setting? 
Not nearly 
enough 
1 
 
Why not? 
Not quite 
enough 
2 
 
Why not? 
 
Just  
right 
3 
More than 
enough 
4 
 
Does the protocol provide the 
minimum standard of care for the 
clinical problem of polypharmacy? 
Not nearly 
enough 
1 
Not quite 
enough 
2 
Just  
right 
3 
More than 
enough 
4 
 
Does the protocol provide the 
minimum standard of care for 
addressing inappropriate prescribing 
in the older adult population? 
Not nearly 
enough 
1 
Not quite 
enough 
2 
Just  
right 
3 
More than 
enough 
4 
 
How much time did it take to 
administer the protocol? (circle one) 
25-30 
minutes 
1 
20-25 
minutes 
2 
15-20 
minutes 
3 
10-15 
minutes 
4 
Feedback: 
Do you feel that the protocol made 
you more aware of the problem of 
polypharmacy and its complications?  
Yes or No  
 
Why or Why 
not? 
   
Feedback: 
Do you feel that the protocol 
modified your prescribing habits to 
avoid inappropriate prescribing in 
older adults? 
 
 
 
Yes or No  
 
 
 
 
 
 
 
Why or why not? 
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Feedback: 
What are the best features of the 
protocol? 
    
Feedback: 
What are the worst features of the 
protocol? 
    
Feedback: 
Please list any suggestions you have 
to improve or change the protocol 
for use in practice. 
    
Adapted from: Paul, S. (1999). Developing practice protocols for advanced practice nursing. AACN Clinical Issues, 10(3), 343-55. 
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Table 2. Nurse Practitioner Satisfaction with the Polypharmacy Protocol Implementation Survey 
 
Question     
How would you rate the 
quality of the Polypharmacy 
Protocol?  
 
Poor 
1 
Fair 
2 
Good 
3 
Excellent 
4 
To what extent did the 
Polypharmacy Protocol meet 
the needs of your practice 
setting? 
 
None of my 
needs have 
been met 
1 
Only a few of 
my needs have 
been met 
2 
Most of my 
needs have 
been met 
3 
Almost all of 
my needs 
have been met 
4 
Did the Polypharmacy 
Protocol help you address the 
problem of polypharmacy and 
inappropriate prescribing in 
your practice setting? 
Didn’t help 
 
1 
Helped some 
 
2 
Helped a  
good bit 
3 
Helped a great 
deal 
4 
Overall, how satisfied are you 
with the Polypharmacy 
Protocol in addressing 
polypharmacy and 
inappropriate prescribing in 
your practice setting? 
 
Very 
dissatisfied 
1 
Dissatisfied 
 
2 
Mostly 
satisfied 
3 
 
Very 
satisfied 
4 
Adapted from: Client Satisfaction Questionnaire (CSQ-8). (Attkisson, & Zwick, 1982). 
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Table 3. Fidelity Instrument for the Polypharmacy Protocol Pilot Study 
 
1. Are the Nurse Practitioners using the Polypharmacy Protocol correctly when reviewing the 
patient’s medication list?  
 
Circle the appropriate percentage: 
• 100% of the time (used all 8 steps of the protocol) 
• 88% of the time (used 7 steps of the protocol) 
• 75% of the time (used 6 steps of the protocol) 
• 63% of the time (used 5 steps of the protocol) 
• 50% of the time (used 4 steps of the protocol) 
• 38% of the time (used 3 steps of the protocol) 
• 25% of the time (used 2 steps of the protocol) 
• 13% of the time (used 1 step of the protocol) 
 
2. What types of adjustments were made by the Nurse Practitioners to the patient’s medication list 
to reduce polypharmacy while using the protocol?  
 
Check Yes or No 
 
Question Yes No 
Were OTC medications added to the med list?   
Was a note made about specialist or recent discharge from hospital with changes to 
med list? 
  
Was the medication list reviewed and adjusted for: Prescribing cascade?   
Was the medication list reviewed and adjusted for: Duplications?   
Was the medication list reviewed and adjusted for: High-risk medications from Table 
2? 
  
Was the medication list reviewed and adjusted for: Matched medication with 
diagnosis? 
  
Was the medication list reviewed and adjusted for: Note any physiologic changes in 
the patient? 
  
Was the medication list reviewed and adjusted for: Decrease dose to lowest effective 
dose? 
  
 
 
 
 
 
 
  
! ! ! !! ! ! !! !! ! !!
89!
3. Did the Nurse Practitioners modify their prescribing habits with the older adults while using the 
protocol? 
 
Check Yes or No 
 
Question Yes No 
Did the nurse practitioners state in the survey that it helped with awareness of 
the problem of polypharmacy? 
  
Did the nurse practitioners state in the survey that it helped modify their 
prescribing habits to avoid inappropriate prescribing in older adults? 
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Table 4. Table of Study Measures 
 
Variable Name Measure Level of  
measure 
Time of 
measurement 
OUTCOME VARIABLE (Nurse Practitioner Process Evaluation) 
Does the protocol include enough 
background information about the 
problem of polypharmacy and 
inappropriate prescribing? 
4-point Likert scale with 
following choices: Not nearly 
enough, Not quite enough, Just 
right, More than enough.  
Ordinal Survey, post-
implementation 
of protocol 
Does the protocol allow the APRN 
freedom to individualize the 
protocol for each patient’s 
medication list review? 
4-point Likert scale with 
following choices: Not nearly 
enough, Not quite enough, Just 
right, More than enough. 
Ordinal Survey, post-
implementation 
of protocol 
Is the protocol feasible/appropriate 
for and APRN in this practice 
setting? 
4-point Likert scale with 
following choices: Not nearly 
enough, Not quite enough, Just 
right, More than enough. 
Ordinal Survey, post-
implementation 
of protocol 
Does the protocol provide the 
minimum standard of care for the 
clinical problem of polypharmacy? 
4-point Likert scale with 
following choices: Not nearly 
enough, Not quite enough, Just 
right, More than enough. 
Ordinal Survey, post-
implementation 
of protocol 
Does the protocol provide the 
minimum standard of care for 
addressing inappropriate 
prescribing in the older adult 
population? 
4-point Likert scale with 
following choices: Not nearly 
enough, Not quite enough, Just 
right, More than enough. 
Ordinal Survey, post-
implementation 
of protocol 
How much time did it take to 
administer the protocol? 
Intervals of time: Less than 10 
minutes, 10-15 minutes, 15-20 
minutes, 20-25 minutes, 25-30 
minutes 
 
Ratio Survey, post-
implementation 
of protocol 
OUTCOME VARIABLE (Nurse Practitioner Satisfaction) 
How would you rate the quality 
of the Polypharmacy Protocol? 
4-point Likert scale with 
following choices: Poor, Fair, 
Good, Excellent 
Ordinal Survey, post-
implementation 
of protocol 
To what extent did the 
Polypharmacy Protocol meet the 
needs of your practice setting? 
4-point Likert scale with 
following choices: None of my 
needs have been met, Only a few 
of my needs have been met, Most 
of my needs have been met, 
Almost all of my needs have been 
met 
Ordinal Survey, post-
implementation 
of protocol 
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Did the Polypharmacy Protocol 
help you address the problem of 
polypharmacy and inappropriate 
prescribing in your practice 
setting? 
4-point Likert scale with 
following choices: Didn’t help, 
Helped some, Helped a good bit, 
Helped a great deal 
 
Ordinal Survey, post-
implementation 
of protocol 
Overall, how satisfied are you 
with the Polypharmacy Protocol 
in addressing polypharmacy and 
inappropriate prescribing in your 
practice setting? 
4-point Likert scale with 
following choices: Very 
dissatisfied, Dissatisfied, Mostly 
satisfied, Very satisfied 
Ordinal Survey, post-
implementation 
of protocol 
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DNP Practice Inquiry Project Conclusion 
 Polypharmacy is common among older adults and increases the risk of adverse 
interactions that may interfere with cognition and cause other adverse events. To avoid this, the 
protocol piloted for the DNP project in a primary care setting has been found to address 
polypharmacy both simply and efficiently. The Polypharmacy Protocol screening instrument can 
be used routinely to guide prescribing practice and reduce polypharmacy in older adult patients. 
It also provides a strategy that can be incorporated into practice to reduce adverse drug reactions, 
improve an older adult’s quality of life, and decrease unfavorable events such as falls, 
hospitalizations, and changes in cognition. 
 
 
 
